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ABSTRACT  
Fibroblast growth factor-2 interaction with vascular cells and basement membrane under 
physiological fluid flow and diabetic hyperglycemia 
Karl Vernon Reisig 
Advisor: Alisa Morss Clyne, Ph.D. 
 
 
 
 
Diabetes is a debilitating disease with a significant impact on global health. People with 
diabetes experience early and accelerated atherosclerosis and are at increased risk of restenosis.  
Though the pathogenesis of atherosclerosis and restenosis are complex, endothelial cells (EC), 
smooth muscle cells (SMC), and basement membrane (BM) play important roles in lesion 
development. Healthy EC regulate SMC function, but EC become dysfunctional in 
hyperglycemia or on glycated collagen, which may alter SMC regulation.  Fibroblast growth 
factor-2 (FGF2), which is produced and released by EC and binds to heparan sulfate 
proteoglycans in the endothelial BM, may be critical to loss of vascular homeostasis.   
Experimental and computational models of BM-FGF2 binding kinetics under static 
conditions are well established in the literature but remain largely unexplored under flow.  To 
investigate BM-FGF2 binding kinetics under fluid flow, BM-FGF2 equilibrium and associative 
binding were measured at various shear stresses.  Surprisingly, BM-bound FGF2 increased up to 
a physiological arterial shear stress of 25 dynes/cm
2
, after which it decreased.  These data suggest 
that FGF2 binding varies with shear stress possibly by a catch-slip mechanism, where applied 
force changes the dissociation constant to either promote (―catch‖) or reduce (―slip‖) binding. A 
computational model of BM-FGF2 interaction incorporating convective-diffusive transport and a 
surface binding reaction was also created.  
BM-bound FGF2 is released over time, after which FGF2 affects both EC and SMC. EC 
and SMC proliferation and intracellular signaling in response to FGF2 were investigated under 
hyperglycemic conditions, including for cells grown on glycated collagen or in high glucose 
media. Glycated collagen did not change EC proliferation or pERK signaling, however pAkt 
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signaling decreased on glycated collagen. This suggests that glycated collagen may decrease 
FGF2 promotion of EC survival. SMC proliferation decreased on glycated collagen, while SMC 
cultured with FGF2 showed no difference in growth.   
Improved understanding of BM-FGF2 binding with flow serves as an initial step in a 
comprehensive model of FGF2 binding to BM and cells under fluid flow. Together with the 
observed altered FGF2 effects on vascular cells, these data motivate the development of improved 
growth factor treatments under physiological and disease conditions.   
   
 
  
 
1 
 
1. INTRODUCTION  
 
 
1.1 Clinical Motivation: Diabetes and Vascular Complications 
Diabetes is a debilitating disease with a significant impact on global health.  23.6 million 
people in the United States (8% of the population) have diabetes, and 57 million people over the 
age of 20 in the United States are pre-diabetic [1]. Worldwide, 285 million people are expected to 
have diabetes in 2010 and diagnosis rates are on the rise. By 2030, nearly 440 million people 
(7.8% of the world population) are estimated to be diagnosed with diabetes [2]. Diabetes is the 
number seven cause of death in adults [1]. 
 Type I diabetes accounts for 5-10% of diabetes cases. Autoimmune destruction of 
insulin-producing pancreatic ß-cells results in a lack of circulating insulin and the inability to 
regulate blood glucose levels.  Type II diabetes, on the other hand, is the most common form of 
diabetes (90-95% of cases) [1]. In Type II diabetes, cells become insensitive and then resistant to 
insulin.  Type II diabetes develops over time and is related to obesity, physical inactivity, family 
history, race/ethnicity, and/or deficient glucose metabolism [1]. The onset of type I diabetes on 
the other hand occurs during childhood and may be associated with genetic or environmental 
causes.  Regardless of the cause or type, diabetes is characterized by unregulated blood glucose 
levels, leading to either hypo- or hyperglycemia. There is currently no cure for diabetes. Patients 
must undergo life-long therapy regimens of modified diet and exercise, insulin injections, and/or 
oral medication.   
Patients with diabetes are at an increased risk of developing cardiovascular disease, both 
at the macrovascular and microvascular level.  Macrovascular disease, including myocardial 
infarction and stroke, is the number one cause of death in people with diabetes [3-4].  
Microvascular complications include diabetic retinopathy which can lead to blindness, diabetic 
nephropathy which can lead to renal failure, diabetic neuropathy which contributes to numbness 
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and gait abnormality, and disordered angiogenesis which is a factor in impaired wound healing  
[5-6].   
People with diabetes experience early and accelerated atherosclerosis, the hardening and 
narrowing of arteries caused by plaque build-up in the arterial wall.  Though the pathogenesis of 
atherosclerosis is complex, both endothelial (EC) and smooth muscle cells (SMC) play an 
important role in atherogenesis over many levels of lesion development. Hyperglycemia, 
hypertension, smoking, insulin resistance, and blood fatty acid levels are risk factors for 
atherosclerosis. Together these factors contribute to EC dysfunction through oxidative stress and 
activation of the protein kinase C and the receptor for advanced glycation end products [7]. EC 
decrease nitric oxide synthesis while increasing synthesis of endothelin-1 and angiotensin-II, 
leading to vasoconstriction and SMC growth and migration. Additionally, dysfunctional EC 
promote inflammation through the up-regulation of NF-κB and activator protein-I [7]. Lastly, the 
vessels become pro-thrombotic through decreased nitric oxide levels and increased tissue factor 
and plasminogen activator inhibitor-I synthesis [7].     
These changes in EC function directly affect SMC behavior. SMC may promote lesion 
formation through migration into the tunica intima, inflammatory cytokine release, and increased 
lipoprotein retention. Together these factors lead to creation of foam cells and fatty streaks [8].  In 
late stage atherosclerosis, SMC help to stabilize the plaque through increased proliferation and 
production of extracellular matrix [9-12].  Hyperglycemia in diabetic atherosclerotic lesions alters 
low density lipoproteins which increase SMC migration and apoptosis [13].  Furthermore, 
diabetic lesions contain fewer SMC than lesions in patients without diabetes, which may increase 
the risk of plaque rupture due to instability [9, 14].     
People with diabetes are also at an elevated risk of developing restenosis following 
angioplasty or stenting.  Percutaneous transluminal coronary angioplasty (PTCA) involves the 
insertion and expansion of a balloon catheter to widen a narrowed (stenosed) blood vessel.  Stents 
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are often implanted during PTCA to prevent rapid elastic recoil and restenosis, the renarrowing of 
a blood vessel.  Restenosis often arises within weeks of PTCA or stenting and is thought to be 
caused by inflammation and vascular cell proliferation related to vessel damage. In the process of 
PTCA there is inevitable damage to the endothelium as the vessel is forcibly expanded.  This may 
cause loss of the EC monolayer, removing the homeostatic and barrier function of EC.  Damaged, 
intact EC may release soluble factors, affecting proliferation and migration of neighboring EC 
and SMC [15]. Furthermore, collagen levels in the extracellular matrix increase [16].  Restenosis 
occurs at rates as high as 30-50% without and 20% with stenting [8, 17-19].  Diabetes is an 
independent risk factor for restenosis, with clinical studies showing increased rates of restenosis 
in people with diabetes following PTCA [20].  The mechanism of increased restenosis in 
hyperglycemia is under debate, with reports indicating it may be caused by collagen-mediated 
affects in the basement membrane [21].     
 
1.2 The Vascular Wall is Composed of Endothelial and Smooth Muscle Cells Separated 
by the Basement Membrane  
EC compose the inner lining (tunica intima) of blood vessels and play an important role 
in vascular homeostasis.  The endothelium responds to physiological changes to regulate vascular 
tone, hemostasis, and inflammation by releasing potent bioactive chemicals.  These molecules 
include paracrine vasodilators (nitric oxide, bradykinin, C-natriuretic peptide) and 
vasoconstrictors (endothelin-1, angiotensin-II, thromboxane A2) [22]. The endothelium also acts 
as a selective barrier, controlling transport into and out of the blood and surrounding tissues.  
Specifically, EC are closely associated through adherens junctions made up of VE-cadherin and 
tight junctions composed of occludins [23].   
The basement membrane (BM) is a subset of the extracellular matrix which separates EC 
and SMC and plays an important role in controlling cell behavior.  Composed of heparan sulfate 
4 
 
proteoglycans (HSPG), laminin, collagen, fibronectin, and other molecules including nidogen and 
entactin, the BM acts as a reservoir for various growth factors. These growth factors include 
fibroblast growth factor-2 (FGF2), with EC and HSPG regulating FGF2 storage and release [24-
25].  HSPG are large macromolecules composed of the glycosaminoglycan heparan sulfate 
covalently bound to a protein core.  The most common type of HSPG found in the BM are 
perlecan and agrin [26]. HSPG are also present on cells as the proteoglycans syndecan and 
glypican [27].  
Located directly beneath the BM in the tunica media, SMC are circumferentially oriented 
at 90° to the flow direction and are important effectors of EC-controlled homeostasis.  SMC 
regulate blood vessel diameter by responding to vasodilators and vasoconstrictors.  SMC also 
respond to mechanical forces in a strain-magnitude dependent manner.  Under typical 
physiological strain levels, SMC have a quiescent, non-synthetic phenotype. In contrast when 
experiencing high strain, SMC become proliferative and produce extracellular matrix proteins 
[28].  A balance of growth factors, including FGF2, also controls SMC phenotype.  SMC play an 
important role in the development of pathologies such as atherosclerosis and restenosis, with 
SMC migration into and proliferation in the tunica intima  Endothelial control of SMC behavior 
is evidenced by research indicating conditioned media collected from non-confluent EC 
stimulates SMC proliferation, whereas media collected from confluent EC inhibits SMC 
proliferation [29-30].  FGF2 is implicated in SMC proliferation since proliferation is inhibited 
when heparin, a FGF2-binding glycosaminoglycan, is added to EC-conditioned media and 
uninhibited with addition of heparinase/heparitinase [31-32].   
 
1.3 The Vasculature is Constitutively Exposed to and Affected by Blood Flow 
EC are continually exposed to mechanical forces due to blood flow. Shear stresses range from 
less than 1 to more than 100 dynes/cm
2 
in vivo, and EC respond to changes in shear stress by 
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altering gene expression, protein production, extracellular signaling, and cell-cell interactions 
[33].  Under normal, healthy flow conditions EC align and become quiescent with flow through 
rearrangement of the actin cytoskeleton. Disturbed flow, which often occurs at vessel bifurcations 
or near valves, can lead to EC misalignment as well as a pro-atherogenic and inflammatory EC 
phenotype [34-35]. EC are also sensitive to shear stress and type of flow. Laminar flow is anti-
apoptotic and prevents EC turnover [36], while turbulent flow is correlated with EC apoptosis 
[37]. When exposed to shear stresses greater than 70 dynes/cm
2
, EC may become pro-thrombotic. 
In contrast, EC in low shear stress regions are susceptible to atherosclerosis [38].  
 
1.4 Vascular Cells and the Basement Membrane Change in Diabetes 
Individual dysfunction of and interaction between EC and SMC plays an important role 
in diabetic complications.  Healthy EC regulate SMC homeostasis, but EC become dysfunctional 
in hyperglycemia, which may alter SMC regulation.  Many factors contribute to these processes, 
including the polypeptide FGF2 [31, 39]. Hyperglycemia and mechanical damage lead to 
increased EC FGF2 release and FGF2 BM storage [40-42]. When cultured in high glucose media, 
EC FGF2 release and permeability increases [43]. This increased hyperglycemic permeability 
may be a factor in vascular lesion formation in diabetes, as increased permeability would allow 
more factors to reach SMC in the vascular media and alter their behavior.   
Glycated collagen directly influences EC behavior in diabetes. Prolonged hyperglycemia 
glycates circulating proteins to form advanced glycation end products (AGE) which can activate 
intracellular signaling after binding to AGE receptors (RAGE) [44-45].  Glycation also occurs in 
the BM, as collagen is glycated at higher rates in people with diabetes. This is hypothesized to 
contribute to late-stage diabetic complications including diabetic nephropathy [46].  Individual 
glycated collagen chains then become cross-linked, which increases BM stiffness and decreases 
vessel elasticity [47] [48-49]. Furthermore, high glucose EC culture decreases HSPG sulfation, 
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though the total secreted HSPG amount does not change [50]. Interestingly, BM FGF2 levels 
increase in high glucose, though the FGF2 binding ability of the BM does not [43]. Additionally 
vascular wall permeability is related to RAGE, as blocking RAGE decreases EC permeability 
both in vitro and in vivo [51].  
 
1.5 Fibroblast Growth Factor – 2 Influences Endothelial and Smooth Muscle Cell 
Behavior 
FGF2, also known as basic FGF, is one of the twenty-two FGF isoforms. FGF2 is an 18-
25 kDa pleiotropic protein critical in development, wound healing, and angiogenesis [52].   
Within the vasculature FGF2 is produced and released by EC and stored in the extracellular 
matrix or BM bound to HSPG [30, 53-55]. FGF2 binds specifically to heparan sulfate rather than 
the protein core, as FGF2 release from the BM occurs either non-enzymatically with heparin or 
heparan sulfate or enzymatically with heparitinase [56-57].  Lastly, BM HPSG controls FGF2 
diffusive transport from the tunica intima to the tunica media, thereby regulating FGF2 effects 
[58].  
On the cell surface FGF2 binds to high affinity tyrosine kinase receptors (FGFR) and low 
affinity HSPG [59-60].  FGF2 association with HSPG has been shown to promote FGFR binding, 
thereby producing a stronger cellular response.[61-62].   Internalization of FGF2-FGFR, FGF2-
FGFR-HSPG, and FGF2-HSPG complexes may all contribute to FGF2 signal transduction [63].  
FGF2 induces EC proliferation, migration, and differentiation [64-65], as well as SMC 
proliferation and migration in vivo [31, 66-68].  Support for the role of FGF2 in SMC mediated 
migration and proliferation has been demonstrated by anti-FGF antibodies depressing SMC 
growth in the tunica media when injected prior to balloon injury [69].  Additionally FGF2 
promotes survival of EC [70] and SMC [71]. 
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FGF2 activates the ERK (extracellular signaling related kinase, alternatively known as 
MAPK, mitogen-activated protein kinase) and Akt (protein kinase B) pathways, which are 
important for EC and SMC proliferation, migration, and survival. Activation of ERK by FGF2 
causes a cascade of events which culminate in pERK entering the nucleus and forming the 
transcription factor AP-1(activator protein-1) [72]. AP-1 induces transcription of various proteins 
related to cellular proliferation and migration. The Akt pathway is important in regulating cell 
survival with activation of Akt by FGF2 having an anti-apoptotic affect.  FGF2 binding to FGFR 
causes Akt phosphorylation which then inhibit apoptosis-related proteins caspase-9, BAD (Bcl-2-
associated death promoter), and ASK-1 (apoptosis signal-regulating kinase 1), thereby enhancing 
cell survival [73].   
FGF2 binding kinetics under static conditions has been extensively examined both 
experimentally and computationally. While HSPG and FGFR can bind FGF2 independently,  
cooperative binding of FGF2, FGFR, and HSPG has been shown to facilitate binding [74]. 
However, ERK activation in SMC can occur in the absence of FGFR, suggesting HSPG may 
function as FGF2 receptors able to induce signaling independent of FGFR [75]. Additionally, 
HSPG facilitates internalization and metabolism of FGF2 in SMC both in experiments and 
simulations [59]. Models have also examined the mechanisms of FGF2 forming complexes with 
FGFR, HSPG, and heparin  [76-77].  Forsten-Williams et al incorporated cooperative and 
competitive binding, and demonstrated changes in ERK signaling when SMC were made HSPG 
and FGFR deficient [78].  Furthermore, one-dimensional diffusion of FGF2 to HSPG and FGFR 
has been modeled, including degradation, internalization and production of each protein [79]. 
Lastly, the role of HSPG in regulating transport through the BM has been measured 
experimentally and examined computationally [58].  
Fluid flow is important to receptor-ligand binding reactions in the circulatory system, 
including leukocyte and platelet adhesion to EC [80-83].  These systems exhibit the ―catch-slip‖ 
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phenomenon, where an applied force changes the binding dissociation constant [84]. According 
to this theory, shear stress enhances leukocyte and platelet adhesion up to 1 dyne/cm
2
 (―catch‖ 
region) while shear stresses greater than 1 dyne/cm
2
 decrease binding (―slip‖ region) [82-83]. 
FGF2 binding in the vasculature occurs in the presence of fluid flow and may similarly be 
regulated by shear stress. However, little work investigating FGF2 binding kinetics with flow has 
been conducted. Only one model has been published that incorporates fluid flow into FGF2 
binding to EC, and it lacks experimental data to verify the model [85].  Therefore we believe it is 
important to experimentally investigate FGF2 binding to HSPG with flow and examine the effect 
of FGF2 on EC and SMC in hyperglycemic conditions. Additionally, development of a 
computational FGF2 binding model with fluid flow would help to elucidate the effects of shear 
stress on BM-FGF2 binding.  
 
1.6 Hypothesis and Objectives 
Patients with diabetes develop accelerated atherosclerosis and experience high restenosis 
rates following stenting, with SMC and EC playing important roles in these pathologies [12, 86].   
SMC proliferate and migrate into the intima, where they help form the vascular obstruction.   
Healthy EC regulate SMC proliferation and migration, but EC become dysfunctional in 
hyperglycemia, which may alter SMC regulation.  EC dysfunction therefore may contribute to the 
formation of atherosclerotic lesions and stenosed vessels.  EC produce FGF2 which binds to 
HSPG in the BM [25, 59].  We have previously shown that EC FGF2 release and BM storage 
increase in high glucose culture [43].  However, experiments investigating EC release and FGF2 
binding kinetics have only been examined in static culture models.  Furthermore, the effect of 
glycated collagen and high glucose culture on FGF2 signaling in EC and SMC is unknown.  We 
hypothesize that increasing fluid flow will decrease binding of FGF2 to the BM. Furthermore, 
we predict that signaling related to proliferation and survival of EC and SMC in response to 
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FGF2 will be less activated under hyperglycemic culture conditions, leading to decreased cell 
growth and increased cell death.  To investigate this hypothesis we explored the following 
specific aims.  
 
Specific Aim 1: Quantify BM-FGF2 binding kinetics and EC FGF2 release under flow 
Damage to EC in the vasculature can expose the BM. Fluid shear stress induces FGF2 
production by EC, and FGF2 may be released to repair the damaged vessel. These changes can 
affect EC and SMC behavior. FGF2 binding kinetics under static conditions are well established 
in the literature [56, 60, 74, 87].  However, FGF2 binding kinetics under fluid flow conditions 
remain largely unexplored.  Because of the clinical implications of vessel damage and the BM 
FGF2 storage capacity, it is important to investigate FGF2 binding kinetics under flow.     
A. FGF2 equilibrium binding and association to EC BM were assessed at various shear stresses.    
B. FGF2 levels in conditioned media and BM below EC exposed to shear stress were examined. 
 
Specific Aim 2: Develop a computational model of BM-FGF2 binding kinetics with flow 
In Specific Aim 1 we experimentally investigated BM-FGF2 binding changes with shear 
stress. Though BM-FGF2 modeling under static conditions is well developed, only one 
computational model of FGF2 binding under flow exists. This is model is inadequate as it lacks 
verification by experimental data and only examines binding of FGF2 to the EC surface [88]. 
Therefore, a new, experimentally verified computational model of BM-FGF2 binding kinetics 
under fluid flow is needed. 
A. A BM-FGF2 computational model incorporating convective-diffusive transport and a surface 
binding reaction was created. 
B. Sensitivity analysis was performed by changing model parameters including FGF2 and HSPG 
availability, and binding rates.   
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C. The model was modified to include observed changes in BM-FGF2 binding with shear stress. 
Specific Aim 3: Determine EC and SMC response to FGF2 in low and high glucose, and on 
glycated collagen 
EC and SMC contribute to diabetic complications.  Specifically, SMC are important 
effectors of EC released FGF2.  Collagen becomes glycated in chronic hyperglycemia, which 
changes the mechanical and biochemical behavior of the BM.  We therefore quantified the effect 
of FGF2 on EC and SMC in high glucose media and on glycated collagen. 
A. EC and SMC proliferation in high glucose and on glycated collagen was investigated.    
B. EC intracellular signaling (ERK, Akt) in response to FGF2 in high glucose and on glycated 
collagen was explored.    
C. EC death in high glucose and on glycated collagen was studied.  
 
1.8 Thesis Organization  
This thesis is composed of five chapters. The first chapter discusses the clinical relevance 
of this research including the role of EC and SMC in vascular homeostasis and the mechanisms of 
vascular dysfunction in diabetes including FGF2 and BM changes. This chapter concludes with a 
statement of the thesis hypothesis and specific aims. 
The second chapter describes the experimental examination of BM-FGF2 binding 
kinetics under fluid flow conditions. Additionally, preliminary results of EC FGF2 release and 
BM storage with shear stress are presented. These data serve as a basis for the BM-FGF2 binding 
kinetics model developed in chapter four. 
In the third chapter the design and development of a computational model of BM-FGF2 
binding under flow is discussed. Modification of the model to incorporate the experimental 
change in BM-FGF2 binding with flow is incorporated through the ―catch-slip‖ phenomenon, 
where an applied force changes the binding dissociation constant.   
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The fourth chapter presents the response of EC and SMC to FGF2 in high glucose culture 
and on glycated collagen. EC and SMC attachment, proliferation, and death in response to FGF2 
in high glucose and on glycated collagen are explored. Lastly, EC and SMC FGF2 proliferative 
and survival signaling are measured.  
The fifth chapter discusses the conclusions that can be drawn from this work as well as 
recommended future research to elucidate mechanisms of EC and SMC dysfunction in diabetes 
and under fluid flow.  
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2.  BM-FGF2 BINDING KINETICS AND EC FGF2 RELEASE UNDER FLOW 
 
2.1 Introduction 
FGF2 binds to both EC and the BM, a specialized extracellular matrix underneath the EC. 
At the cell surface, FGF2 binds to high affinity FGF2 receptors (Kd 10
-9—10-12 M) and low 
affinity HSPG (Kd 10
-8—10-9 M) [60, 74, 87]. In the BM, FGF2 binds to HSPG which protects 
FGF2 from degradation and denaturation [62, 74]. Fluid shear stress induces FGF2 production by 
EC, and FGF2 may be released to repair damaged vessels [89]. Damage to EC in the vasculature 
can expose the BM. FGF2 binding kinetics under static conditions are well established in the 
literature [56, 60, 74, 87]. Fluid flow is important to receptor-ligand binding reactions in the 
circulatory system including leukocyte and platelet adhesion to EC [80-83].  However, FGF2 
binding kinetics under fluid flow conditions remains largely unexplored. Because of the clinical 
implications of vessel damage and the BM FGF2 storage capacity, it is important to investigate 
FGF2 binding kinetics under flow.     
 FGF2 binding kinetics under static conditions has been extensively examined by 
experiment. On the cell surface HSPG and FGFR can both bind FGF2 independently,  but 
cooperative binding of FGF2, FGFR, and HSPG has been shown to facilitate binding [74]. HSPG 
facilitates internalization and metabolism of FGF2 in SMC as HSPG deficient SMC internalized 
less FGF2 and were unable to prevent intracellular FGF2 degradation compared to HSPG-
expressing SMC [59]. However, SMC signaling can occur in the absence of FGFR, suggesting 
HSPG may function as FGF2 receptors and are able to induce signaling independent of FGFR 
[75]. When cells are made both HSPG and FGFR deficient, SMC ERK signaling is nearly 
eliminated indicating the importance of HSPG in FGF2 affecting cells [78].  FGF2 stored in the 
BM can be released either non-enzymatically with heparin and heparan sulfate or enzymatically 
with heparitinase [56-57].  Lastly, HSPG regulates FGF2 passage through the BM, as non-heparin 
binding FGF2 transports two-fold faster through the corneal BM than normal FGF2 [58]. This 
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indicates the specificity of FGF2 for binding HSPG in the BM and that HSPG functions both in 
the cell surface and in the BM. 
Experimental measurement of FGF2 binding kinetics to both cells and BM under static 
conditions are well established in the literature [56, 60, 74, 87].   However, FGF2 binding kinetics 
under fluid flow remains largely unexplored.  EC and bare BM are continually exposed to shear 
stresses ranging from less than 1 to more than 20 dynes/cm
2
 from blood flow in capillaries and 
arteries, respectively, and EC release FGF2 when experiencing shear stress [89].  Fluid flow is 
important to other receptor-ligand binding reactions, including leukocyte adhesion to EC via P 
and L-selectin [80-82], platelet adhesion mediated by glycoprotein receptor Ibα and von 
Willebrand factor [83],  transport and attachment of drug delivery microbubbles using 
streptavidin-biotin interaction [90], and adhesion of FimH expressing Escherichia coli to 
mannose [91-92].  These systems exhibit the ―catch-slip‖ phenomenon, where an applied force 
changes the binding dissociation constant to enhance and then reduce binding, depending on the 
magnitude of the force [84]. According to this theory shear stress enhances leukocyte and platelet 
adhesion up to 1 dyne/cm
2
 (―catch‖ region) while shear stresses greater than 1 dyne/cm2 decrease 
binding (―slip‖ region) [82-83]. For example, force applied to the epidermal growth factor 
domain in selectin is hypothesized to change the overall conformation of the PSGL-1 and selectin 
interaction to improve binding at low force (catch) and reduce binding at higher forces (slip) [93]. 
Despite the fact that FGF2 affects vascular cells while experiencing flow, no previous 
measurement of FGF2 binding kinetics with fluid flow has been performed.  
FGF2 binding kinetics under fluid flow conditions is critical to fully understanding 
physiologic binding kinetics in the vasculature.  We hypothesized that FGF2 binding to the 
endothelial BM would decrease as fluid shear stress increased and that EC exposed to shear stress 
would release FGF2 into the media and BM.  BM-FGF2 equilibrium and associative binding 
were measured at various shear stresses, and conditioned media and BM FGF2 levels from EC 
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exposed to flow were quantified as well.  We now show that FGF2 equilibrium binding varies 
with shear stress possibly by a catch-slip mechanism, since BM-FGF2 binding peaks at a shear 
stress of around 25 dynes/cm
2
. This improved understanding of BM-FGF2 binding with flow 
enriches current knowledge of FGF2 binding kinetics, serves as an initial step in a comprehensive 
model of FGF2 binding to cells and BM with flow, and motivates the development of better 
treatment methods for which dynamic binding in the presence of flow is important.   
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2.2 Methods  
2.2.1 Cell culture 
Porcine aortic endothelial cells (EC) were isolated from porcine aortae by collagenase 
dispersion and used between passages 4 and 9 [94].  EC were maintained in Dulbecco’s 
Modification of Eagle’s Medium (DMEM, 5 mM glucose) with 5% fetal bovine serum, 1% 
penicillin and streptomycin, and 2% glutamine (Invitrogen) at 37°C and 5% CO2 in a humid 
environment.  Cultures were fed every 2 days and passaged using 0.025% trypsin-EDTA 
(Invitrogen).   
 
2.2.2 Endothelial basement membrane isolation 
To prepare endothelial BM, 1×10
6
 EC were seeded on sterile plain glass microscope 
slides (7.5 × 2.5 cm, VWR) in 100 mm tissue culture dishes and cultured for four days with a 
media change after two days.  Cells were then lysed in 20 mM NH4OH with 0.5% Triton X-100, 
after which isolated BM samples were thoroughly washed with phosphate buffered saline (PBS) 
[41].   Phase contrast microscopy (Nikon Eclipse TS 100) confirmed that the BM remained intact, 
adherent to the glass slide, and free of cell debris.  BM was either used immediately or stored for 
up to four days at 4°C in PBS.  Basal BM FGF2 levels were determined by extracting FGF2 using 
a salt buffer (2 M NaCl, 20mM HEPES, pH 7.4) and quantifying FGF2 levels in the salt buffer 
using an FGF ELISA (R&D Systems). 
 
2.2.3 FGF2 binding kinetics under fluid flow 
Isolated BM on glass slides was exposed to 10 mL of 0 or 10 ng/mL FGF2 in binding 
buffer (25mM HEPES, 0.05% gelatin, pH 7.4) in a parallel plate flow chamber (channel 
dimensions: 6 cm × 1 cm × 0.0127 cm, Glycotech).  A peristaltic pump (Ismatech) was used to 
drive flow, with a bubble trap placed upstream of the channel to preventing bubble damage to the 
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BM. Previous work that the pulsatile affect of the peristaltic pump was negligible and therefore 
was assumed to produce steady flow.  For BM FGF2 equilibrium tests, the BM was exposed to 
the FGF2 solution for 1 hour over shear stresses ranging from 1-122 dynes/cm
2
.  Shear stress 
values were calculated using the equation:  
  (Equation 2.1) 
In this equation τ is shear stress, µ is dynamic viscosity, Q is flow rate, b is channel 
width, and h is channel height. This equation is developed from the Navier-Stokes equation under 
the assumptions that the fluid is Newtonian, flow is laminar and fully developed, and the aspect 
ratio (width to height ratio) is high for the chamber. Over the range of flow rates the Reynold’s 
number defined as  
    (Equation 2.2) 
where ρ is the fluid density, varied from 0.38 to 46.44 and the aspect ratio of the channel was 
78:1, thereby satisfying the assumptions.  Plots of flow rate versus shear stress and the Reynolds 
number can be found in Figures 2.1 and 2.2. 
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Figure 2.1: Relationship between flow rate and shear stress in the Glycotech flow chamber. Shear stress 
was calculated according to Equation 2.1. µ was 9.33×10
-4 
Pa*s at room temperature (22°C) and 7.6×10
-4 
Pa*s at 37°C. Channel height and width were 0.0127 and 1 cm, respectively.  
 
 
 
Figure 2.2: Relationship between flow rate and the Reynolds number in the Glycotech flow chamber. 
Reynolds number was calculated according to Equation 2.2. The ρ was 998 kg/m3 at room temperature 
(22°C) and 994
 
kg/m
3
 at 37°C. 
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All components of the flow apparatus were connected using silicone tubing. Previous 
work has shown there is significant loss of FGF2 in flow experiments due to non-specific binding 
to tubing at low shear stress [95].  However we found binding of FGF2 to tubing to be 
insignificant and not dependent on shear level, as less that 2% of FGF2 in solution was lost to 
binding of tubes (Figure 2.3).  
 
 
Figure 2.3: Non-specific binding of FGF2 to tubing was minimal. To assess the extent to which FGF2 in 
binding buffer solution was lost to non-specific binding to assembly tubing, 10 ng/mL FGF2 was re-
circulated over never-used silicone tubing for 1 hour. Tubes were washed with PBS at a shear stress of 12 
dynes/cm
2
 for 5 minutes. FGF2 bound to tubing was collected using salt buffer and measured by ELISA.  
 
 
Therefore, no correction for loss of FGF2 to tubing was needed. Static control BM 
samples were exposed to the same FGF2 binding solution in 100 mm tissue culture dishes under 
gentle orbital rocking.  BM FGF2 association was measured by exposing BM to 10 ng/mL FGF2 
in binding buffer at 0, 25, and 74 dynes/cm
2
 for 0 to 4 hours.  For both equilibrium and 
association assays, BM FGF2 was extracted after each incubation period using a salt buffer  and 
quantified by FGF ELISA.  For association experiments, basal BM FGF2 level was subtracted 
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from each sample to normalize the initial BM FGF2 level to zero.  All BM-FGF2 binding kinetic 
experiments were conducted at room temperature.  Graphic representation of the experimental 
flow setup is shown in Figure 2.4. All conditions were conducted at room temperature. 
 
 
Figure 2.4: Simplified schematic of FGF2 binding flow experiments.  
 
 
2.2.4 FGF2 Release and BM storage from EC exposed to flow  
To measure EC release and BM storage of FGF2 under shear stress, 1×106 EC were 
seeded on sterile plain glass microscope slides (7.5 × 2.5 cm, VWR) in 100 mm tissue culture 
dishes and cultured for four days with a media change after two days.  Glass slides covered with 
confluent EC were then assembled in the Glycotech flow chamber.  EC FGF2 release was 
quantified by re-circulating 15 mL complete media (DMEM, 5 mM glucose, 5% FBS, 1% PSG)  
at a shear stress of 0, 5, or 20 dynes/cm
2
 and measuring media FGF2 levels over time by FGF 
ELISA.  A graphic representation of the experimental flow setup is shown in Figure 2.4 above 
with intact EC residing on the BM. Static controls were run in 100 mm tissue culture dishes, and 
both static and flow samples were conducted at 37°C and 5% CO2.  FGF2 storage in the BM was 
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determined by removing EC with lysis buffer, extracting FGF2 with salt buffer, and quantifying 
by FGF ELISA.  
 
2.2.5 Statistical Analysis 
Statistical analyses were conducted using the Microsoft Excel Data Anaylsis ToolPak.  
Data is presented graphically as mean ± standard deviation of single experiments.  Comparisons 
between two groups were analyzed by Student’s t-test, while comparisons between more than two 
groups were analyzed by ANOVA.  A value of p < 0.05 was considered statistically significant 
and shown in figures with an asterisk sign (*). 
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2.3 Results 
2.3.1 FGF2 specific binding to basement membrane and non-specific binding to glass 
change with shear stress 
FGF2 equilibrium binding to both isolated endothelial cell BM and bare glass under static 
and fluid flow conditions was measured to determine changes in specific and non-specific 
binding, respectively, with shear stress.  Surprisingly, BM-FGF2 binding at 25 dynes/cm
2
 shear 
stress was significantly higher than in static conditions, while non-specific binding to glass was 
virtually eliminated (Figure 2.5).  BM produced by EC after four days contained a basal level of 
266.2 ± 71.6 pg/cm
2
 FGF2 due to EC FGF2 synthesis and BM deposition. BM FGF2 increased 
significantly when exogenous FGF2 was added under either static or flow conditions, since BM 
as produced by EC was not saturated with FGF2.  However, BM bound more than twice as much 
FGF2 at 25 dynes/cm
2
 shear stress as compared to static conditions.  While this difference was 
not statistically significant due to low sample number, when FGF2 binding was corrected for non-
specific binding to glass [96], the change in BM-FGF2 binding with shear stress became 
significant.  In direct contrast, FGF2 non-specific binding to glass decreased nearly 200 fold 
under fluid flow conditions when compared to static incubation.   
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Figure 2.5: FGF2 specific binding to basement membrane and non-specific binding to glass changed with 
shear stress. Uncorrected static and 25 dynes/cm
2
 represent the amount of FGF2 bound after treatment 
with FGF2 for 1 hour. Corrected samples are adjusted for non-specific binding to glass by subtracting 
30% of FGF2 bound to glass from BM values at 0 or 25 dynes/cm
2
.  
 
 
To ensure that fluid flow exposure did not affect BM biochemical or structural integrity, 
BM was exposed to 0, 25, and 122 dynes/cm
2
 shear stress for one hour, after which BM-FGF2 
equilibrium binding and BM adherence to glass were assessed (Figure 2.6). The ability of BM to 
bind FGF2 did not change after shear stress exposure, indicating that shear stress did not affect 
BM HSPG binding site availability (Figure 2.6A). Phase contrast images of BM taken before and 
after shear stress exposure revealed that BM remained intact and adhered to glass, suggesting that 
BM structure did not change (Figure 2.6B).  
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Figure 2.6: Shear stress did not change the BM HSPG availability or adherence to glass. (A)  BM 
equilibrium FGF2 binding does not change after exposure to shear stress. (B) Phase contrast images of 
isolated endothelial BM before and after shear stress exposure show that BM remained intact. Scale bar = 
100 µm.  
 
 
2.3.2 Equilibrium FGF2 binding to the BM peaks at around 25 dynes/cm
2
 shear stress 
FGF2 binding to both BM and glass was then measured over a wider shear stress range to 
determine the relationship between binding kinetics and fluid flow.  BM-FGF2 equilibrium 
binding peaked at a shear stress of around 25 dynes/cm
2
 (p < 0.05 compared to 1 dyne/cm
2
) then 
rapidly decreased at higher shear stress levels (Figure 2.7).  The amount of BM-bound FGF2 at 
74 and 122 dynes/cm
2
 shear stress was similar to FGF2 bound at 1 dyne/cm
2
.  However, 
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increased shear stress consistently reduced FGF2 binding to glass (Figure 2.7 inset).  At and 
above 25 dynes/cm
2
 shear stress, less than 10 pg/cm
2
 FGF2 was bound to glass. 
 
  
Figure 2.7: FGF2 binding to the endothelial BM peaked at 25 dynes/cm
2
. BM was exposed to 10 ng/mL 
FGF2 for 1 hour at shear stresses ranging from 0 to 122 dynes/cm
2
. Bare glass slides were the control for 
non-specific binding. Inset is binding to glass. * indicates p<0.05 compared to 1 dyne/cm
2
.  
 
 
The variation in BM-FGF2 binding with shear stress was not related to differences in 
FGF2 association. The final amount of BM-bound FGF2-2 was highest at 25 dynes/cm
2
 shear 
stress and similar at 0 and 74 dynes/cm
2
 shear stress, which was consistent with equilibrium 
binding results (Figure 2.8). Yet regardless of shear stress level, BM-FGF2 association increased 
rapidly to 77-79% of maximum binding after one hour compared to the final amount bound 
(normalized data in Figure 2.9). 
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Figure 2.8: FGF2 BM association depended on shear stress. BM was exposed to 10 ng/mL FGF2 for 4 
hours at shear stresses of 0, 25, and 73 dynes/cm
2
.  
 
 
Figure 2.9: FGF2 BM association time to equilibrium did not vary with shear stress. Each FGF2 
concentration at 0, 25, and 73 dynes/cm
2
 in figure 2.5 was scaled according to their respective FGF2 
concentrations after 4 hours.  
 
 
2.3.3 Endothelial cells release FGF2 into the BM and media when exposed to shear 
stress 
FGF2 content in the endothelial BM after intact EC were exposed to flow for six hours 
was also assessed.  BM-FGF2 levels after six hours showed a 2.44-fold increase over static 
controls at a shear stress of 5 dynes/cm
2
 to 1,201 ± 84 pg/cm
2 
from 587.9 ± 32.4 pg/cm
2
 under 
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static conditions (p < 0.05, Figure 2.10). However, BM FGF2 levels isolated after EC 
experienced 20 dynes/cm
2
 were not significantly different from static controls, with 534.3 ± 184.9 
pg/cm
2
 FGF2 present.  
 
 
Figure 2.10: BM FGF2 levels increase after EC are exposed to 5 dynes/cm
2
 shear stress. EC were exposed 
to shear stress for 6 hours using the set-up shown in Figure 2.1. n = 4 for static samples, while n = 2 for 5 
and 20 dynes/cm
2 
samples. 
 
Release of FGF2 by EC exposed to flow was also measured; however unlike BM FGF2 
levels there was not a significant change in culture medium FGF2 levels between different shear 
stresses.  EC experiencing 5 and 20 dynes/cm
2
 released FGF2 into the medium within 15 minutes 
of being exposed to flow, causing the total FGF2 concentration to increase 1.88 and 3.22 fold 
(Figure 2.11).  However the increase in FGF2 was not significant compared to the initial amount 
of FGF2 in the media (p = 0.057 and p = 0.63 for 20 and 5 dynes/cm
2
).  For the remainder of 
testing, the amount of FGF2 in the culture medium remained elevated.  EC cultured statically also 
did not change their release of FGF2 over time (p = 0.146).  Overall FGF2 concentrations ranged 
from 1.83 to 20.18 pg/(1×10
6
 cells).  
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Figure 2.11: EC exposed to shear stress released FGF2 into the culture medium. To compare the change in 
FGF2 concentration, the amount of FGF2 in each sample was normalized according to the number of EC 
exposed to flow and the initial amount of FGF2 in the media.   
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2.4 Discussion 
BM-FGF2 binding kinetics has not previously been explored under physiologic flow 
conditions.  Here we show that equilibrium BM-FGF2 peaked at 25 dynes/cm
2
 shear stress, a 
typical arterial shear stress [97], whereas time to equilibrium was governed by convective 
transport.  In contrast, non-specific FGF2 binding to glass was significant under static conditions 
but rapidly diminished with application of fluid flow.  These results suggest that forces 
encountered by HSPG-FGF2 complexes may regulate FGF2 binding to the BM, an important 
consideration when studying vessel response to intimal or EC damage.  Therefore, FGF2 binding 
kinetics assays to BM HSPG, as well as cell surface HSPG and FGF2 receptors, should be 
performed under relevant physiological conditions to more accurately characterize and 
understand the role of fluid flow in this system.  
BM-FGF2 storage plays an important part in vascular function both in healthy and 
pathological conditions and changes in BM-FGF2 binding with flow may affect where cell-
released or exogenously administered FGF2 plays a role.  EC release FGF2 both in vitro and in 
vivo following injury [40, 69], and numerous groups have administered FGF2 to promote 
angiogenesis [98-100].  Increased BM-FGF2 binding affinity at arterial shear stress levels may 
facilitate BM-FGF2 binding in large arteries rather than in capillaries where the shear stress levels 
are significantly lower (1-4 dynes/cm
2
).  While arterial FGF2 helps repair damaged vessels, 
prolonged FGF2 release may lead to intimal thickening and should be avoided [69].  
Additionally, if FGF2 effects are desired in the capillaries, FGF2 may need to be administered 
close to the capillary level to avoid excessive binding and depletion of FGF2 in the arteries.   
BM-bound arterial FGF2 may also be preferentially released in areas of disturbed flow, where 
shear stress is reduced or variable, such as at an arterial bifurcation, an atherosclerotic plaque, or 
an implanted vascular device such as a stent.  In some cases, excess FGF2 release may promote 
vascular healing; however it could also significantly contribute to intimal lesion formation. 
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FGF2 binding under flow appears to exhibit force dependent ―catch-slip‖ bond behavior, 
as seen in other receptor-ligand mediated binding in the circulatory system.  We hypothesize that 
―catch‖ behavior, where applied force proportionally decreases dissociation rate, may govern 
increased BM-bound FGF2 with increasing shear stress.  The abrupt decline in equilibrium 
binding at shear stresses greater than 25 dynes/cm
2 may be explained by a ―slip‖ behavior, where 
dissociation rate increases proportionally with shear stress above a threshold shear level.  Catch-
slip behavior has primarily been identified and characterized in binding interactions between 
blood cells and their EC surface receptors.  PSGL-1 on leukocytes binds with P or L-selectins, 
and glycoprotein receptor Ibα on platelets interact with von Willebrand factor on the EC surface, 
respectively [83, 101-102].   
HSPG binding to FGF2 has some similarities to PSGL-1 binding to P-selectin which 
suggest that both may be regulated by the catch-slip phenomenon with flow. Interaction of PSGL-
1 (a glycoprotein) and HSPG (a proteoglycan) with their ligands depends on multiple moieties 
working in concert.  PSGL-1 binding to P-selectin requires both sialyl Lewis x O-glycans and 
sulfonated tyrosine amino acids on PSGL-1 to come into close contact with the lectin domain of 
P-selectin [93, 103]. FGF2 relies on specific peptide regions interacting with N- and O-sulfated 
sugars [104] as well as non-sulfated carbohydrate groups within HSPG [105-106] to form the 
binding complex. Application of force such as during fluid flow may shift binding towards a 
more stable conformation. For example, force applied to the epidermal growth factor domain in 
selectin is hypothesized to change the overall conformation of the PSGL-1 and selectin 
interaction to improve binding at low force (catch) and reduce binding at higher forces (slip) 
[102].  A similar mechanism may also occur in FGF2 and HSPG interaction with flow, with 
force-induced conformational change of the HSPG-FGF2 binding complex modifying binding 
affinity. Alternatively, as long flexible molecules, fluid flow may expose additional binding 
regions within PSGL-1 and HSPG at low shear stresses, increasing their ligand storage capability, 
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while high shear stress may cause HSPG to fold over itself and reduce the number of available 
binding sites. 
Though FGF2 binding shows similar catch-slip binding kinetics as leukocytes and 
platelets, the shear stress at which leukocyte and platelet adhesion peaks (1 dyne/cm
2
) is much 
lower than the shear stress at which FGF2 binding peaks (25 dynes/cm
2
) [82-83].  This may be 
related to geometric or physiologic differences between these systems.  Both leukocytes and 
platelets have radii on the order of microns while FGF2 has a hydrodynamic radius of 14.5 Å 
[58], about a 1000-fold difference.  As a result, the cross-sectional area presented by leukocytes 
and platelets to flow is much greater than that presented by FGF2, which results in a higher drag 
force for a given flow rate.  Thus the forces at which binding increases and decreases may be 
similar, but these forces would occur at dramatically different flow rates and shear stresses.  This 
effect could be studied by functionalizing particles of varying size with a constant density of a 
known catch-slip ligand such as PSGL-1, and measuring particle binding density, residence time, 
and forces necessary to enhance (decrease koff) or reduce binding (increase koff) to a selectin-
coated surface.  The forces could then be normalized based on particle size and ligand density, 
and a relationship between force and binding strength revealed.  Alternatively, the disparity in 
peak binding shear stress may be explained by the biological function of leukocytes and platelets. 
Leukocytes and platelets primarily accumulate on the vascular surface in post-capillary venules, 
where wall shear stresses are on the order of 1 to 4 dynes/cm
2 
[83, 107].  However, FGF2 can be 
released from EC or the BM at any location.  Therefore, it is possible that FGF2 maximally binds 
to the BM in areas of high shear stress such as arteries where vessel damage must be rapidly 
repaired.  
In our experiments, we measured FGF2 binding under flow conditions to BM that was 
produced by EC under static conditions. Though isolated BM remained biochemically and 
physically stable even at high flow rates, shear stress may change HSPG binding site 
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concentration in the BM or endothelial cell BM production in flow culture.  Experimental 
application of shear stress to the BM did not affect its ability to bind FGF2 statically, suggesting 
that force did not permanently change HSPG stability or distribution. It is possible that once the 
force due to shear stress is removed, BM changes are reset, thereby causing us to miss such a 
change.  BM created by EC exposed to shear stress may also be different from BM secreted in 
static culture both in HSPG amount and distribution.  For example, BM produced under flow 
have additional endothelial cell adhesion sites, aligned structural proteins, or contain more HSPG 
to ensure secreted factors are stored in the BM and not swept away by flowing blood.  Future 
work should include studying BM-FGF2 binding kinetics to BM produced under various flow 
rates.  
Release of FGF2 into the BM and circulating culture medium by EC exposed to shear 
stress was also measured. Interestingly, BM FGF2 levels with EC intact increased at 5 dynes/cm
2
 
while EC experiencing 20 dynes/cm
2
 of shear stress did not increase the amount of FGF2 in the 
BM compared to static controls.  Similarly, culture medium FGF2 levels may have increased 
when EC were exposed to flow, but the results were inconclusive due to large sample variation. 
Previous work indicates that EC increase FGF2 protein levels and gene expression when exposed 
to 36 dynes/cm
2
 and to a lesser extent 15 dynes/cm
2
 [89].  It is possible that our shear stresses 
were not high enough to induce sufficient FGF2 release.  While binding of FGF2 to bare BM only 
depends upon binding kinetics and transport, the presence of EC in the system complicates this 
process.  When exposed to flow, EC may change permeability, morphology, and the production 
and/or use of FGF2.  Therefore, the preliminary results of increased BM FGF2 levels when intact 
EC are exposed to 5 dynes/cm
2
 but no change after exposure to 20 dynes/cm
2
 are difficult to 
interpret.  One possible reason for the increase in BM FGF2 at 5 dynes/cm
2
 and no change in 
medium FGF2 levels is that early exposure to shear stress (1 minute – 1 hour) caused an up-
regulation of FGF2 production/release [33].  In the case of 5 dynes/cm
2
, this rapid increase may 
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not be needed by EC to change their morphology or for survival, so FGF2 is deposited into the 
BM.  In the case of higher shear stresses, EC may release FGF2 in order to facilitate survival by 
the AKT pathway [73] or maintain the barrier role of the endothelium, so the EC use the FGF2 
rather than deposit it in the BM.  However in order to understand the effect of shear stress on EC 
release into culture medium and deposition in the BM much more detailed studies must be 
conducted, including permeability experiments, measurement of FGF2 production, and 
quantification of FGF2 binding kinetics including release from and binding to EC. 
In all flow experiments the sample size was restricted to two due to time constraints and 
the experimental setup.  As a result certain data points narrowly missed the cutoff (p < 0.05) for 
statistical significance, such as BM-FGF2 binding static vs. 25 dynes/cm
2
 shear stress conditions 
(p ~ 0.06) and the release of FGF2 into the media by EC exposed to flow. Each experiment was 
repeated multiple times and similar trends were observed.  While combining experiments would 
have produced a statistically significant difference in additional cases, we chose to show 
representative single experiments due to variations in applied FGF2 degradation and FGF2 
ELISAs. We were able to achieve significance within a single experiment by correcting BM 
bound FGF2 for non-specific binding to glass.  This adjustment was based upon our previous 
work showing that ~30% of the BM sample area is exposed culture substrate to which FGF2 can 
non-specifically bind [96].  The BM is known to have a large capacity for FGF2 storage, which is 
significantly greater than the amount of FGF2 stored in the BM basally under in vitro culture 
conditions [43, 96]. BM-bound FGF2 in our experiments ranged from 266 pg/cm
2 
under basal 
conditions to 2800 pg/cm
2 
when 10 ng/mL FGF2 was added.  These concentrations are slightly 
higher than previously published results [43, 96].  This disparity may be explained by differences 
in culture conditions (substrate, media, cell source) as well as variations in FGF ELISA, BM 
isolation, and FGF2 collection method. 
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We now show that BM-FGF2 binding is shear stress-dependent, with equilibrium BM-
FGF2 peaking at a shear stress near 25 dynes/cm
2
.  FGF2 non-specific binding decreases quickly 
with shear stress, which suggests that FGF2 needs to be specifically bound to a surface to remain 
present under fluid flow conditions.  BM-FGF2 also increased when intact EC experienced 5 
dynes/cm
2
, but did not change at 20 dynes/cm
2
.  As a next step in chapter 3 a computational 
model of BM-FGF2 binding in fluid flow will be developed.  
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3.  DESIGN OF A NOVEL COMPUTATIONAL MODEL OF BM-FGF2 INTERACTION 
WITH FLUID FLOW 
 
3.1 Introduction and Problem Statement  
In chapter two we showed experimentally that BM-FGF2 binding changes with shear 
stress possibly by a catch-slip mechanism, since BM-FGF2 binding peaks at a shear stress of 
around 25 dynes/cm
2
. The processes involved in FGF2 binding, storage, and release is complex 
and therefore would benefit from the development of a physiologically relevant computational 
model.  Though BM-FGF2 binding kinetics models under static conditions are well developed 
only one computational model of FGF2 binding under flow exists.  However, this model lacks 
verification by experimental data, only describes FGF2 binding prior to equilibrium, and only 
examines FGF2 binding to the EC surface [85].  Therefore, a computational model of BM-FGF2 
binding kinetics with fluid flow was created as an initial step towards creating a comprehensive 
model of FGF2 binding kinetics under physiological conditions. 
FGF2 binding kinetics under static conditions have been extensively modeled 
computationally to determine FGF2 effects on cell signaling [108] as well as the role of FGF2-
FGFR-HSPG complex formation [76-77], degradation, and internalization [109].  These models 
were developed in conjunction with experimental data, either by running experiments in parallel 
or selecting model parameters, such as protein concentrations and binding constants, according to 
experimental results.  FGF2 interaction with SMC, including binding of FGF2 to cell surface 
FGFR and HSPG as well as FGF2 intracellular distribution and metabolism after binding, has 
been researched.  In both experiments and a model, HSPG deficient SMC internalized less FGF2 
and were unable to prevent intracellular FGF2 degradation when compared to HSPG-expressing 
SMC [59]. Additionally a model of interaction among heparin, HSPG, FGF2, and FGFR 
demonstrated that soluble heparin facilitated FGF2 binding to FGFR [77].  A model incorporating 
one-dimensional FGF2 diffusion with FGF2 binding to HSPG and FGFR was also created.  When 
35 
 
FGF2, HSPG, and FGFR production, degradation, and internalization were included, the FGF2-
FGFR-HSPG triad complex was most effectively internalized when dimerized with another triad  
[109]. Lastly, the role of HSPG in regulating transport through the BM was measured 
experimentally and examined computationally.  Rapid reversible FGF2-HSPG binding was 
shown to regulate FGF2 transport through the BM, with increasing HSPG concentrations 
inhibiting transport [58]. These models were solved using readily accessible engineering 
programs and solvers including the MATLAB stiff ordinary differential equation solver [108-
109] and Fortran procedures [58, 77].  
Computational modeling of FGF2 binding kinetics under fluid flow conditions, in 
contrast to static conditions, remains largely unexplored.  Only one model has been published that 
incorporated fluid flow into a computational model of FGF2 binding to EC [85].  This model 
examined incompressible Navier-Stokes flow through a cylindrical bioreactor with both 
convective and dissipative FGF2 transport.  The binding kinetics of FGF2 to HSPG and FGFR on 
the EC surface was determined. As in previous static models [77, 108] the flow model 
incorporated FGF2, FGFR, and HSPG dimer and trimer complex formation.  Fluid viscosity and 
density were chosen to approximate whole blood, though the model did not account for the 
presence of circulating blood cells in the flow profile or FGF2 transport calculations.  Flow rates 
were chosen similar to those experienced in capillaries (shear stresses on the order of 1 
dyne/cm
2
).  The model was solved using the SIMPLER algorithm for the Navier-Stokes equation 
and the backward differencing method for the ordinary differential equations representing the 
binding process.  
Despite their comprehensive approach, this model has several limitations. It only 
describes FGF2 binding to cells and does not consider binding to the BM.  Additionally model 
results are not compared to experimental data to verify the model, though model input parameters 
such as FGF2, HSPG, and FGFR concentrations and binding constants were selected based on 
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previous work [85, 108].  Furthermore, the model only explores pre-equilibrium binding, rather 
than characterizing equilibrium binding. Lastly, the effect of different shear stresses on FGF2 
transport and binding was not investigated.   
To address the lack of an experimentally-validated model of FGF2 binding to BM HSPG 
with flow, we developed a computational model of BM-FGF2 interaction incorporating 
convective-diffusive transport and a surface binding reaction.  Sensitivity of the model to varying 
inputs was also examined.  The model was modified to include a catch-slip binding mechanism to 
account for the change in BM-FGF2 binding with flow.   
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3.2 Model Development 
3.2.1 Objectives, constraints and criteria 
Three modeling objectives were established to create a computational model of BM-
FGF2 binding in fluid flow.  The main model objective was to computationally investigate the 
effect of convective transport on FGF2 binding to BM HSPG and to compare the computational 
to experimental results.  Model fluid flow needed to vary from 0-122 dynes/cm
2
, and FGF2 and 
HSPG concentration need to encompass a ranged from 0.01 to 10000% of experimental values. 
Second, the model needed to incorporate complex fluid flow effects on binding kinetics through 
thoughtful model design modifications, including application of the catch-slip phenomenon, 
where applied force changes the reaction dissociation constant. Model variables, including 
reaction constants (kon and koff), must be changeable with fluid flow.  Finally, the model needed to 
be reproducible and computationally efficient, requiring as little memory and runtime as possible 
to converge to a stable solution on a typical desktop computer.  Model outputs, such as FGF2 
concentration in solution and FGF2-HSPG complex concentration, must be defined and easy to 
ascertain over all times and shear stresses.  In conclusion, a successful model should help explain 
BM-FGF2 binding with flow experimental results and serve as a platform from which to develop 
more complex models. 
 
3.2.2 Model development with non-varying association and dissociation constants 
A simplified computational model of BM-FGF2 binding kinetics under flow was 
developed using COMSOL Multiphysics
®
 (version 3.4).  COMSOL is a finite-element analysis 
and solver program which is useful for analyzing a variety of engineering problems including 
structural and fatigue material analysis, non-isothermal flow, mass transport, and electric field 
effects.  Additionally COMSOL has been used to model biomedical engineering phenomena such 
as drug release from a degradable biomaterial matrix, plastic deformation during stent expansion, 
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and flow through microfluidic devices [110].  COMSOL is uniquely suited for solving complex 
modeling problems which require coupling of different phenomena, such as the convective and 
diffusive transport and surface binding reaction present in our experiments.  For these reasons as 
well as its relative ease of use, COMSOL was chosen as the programming platform for the model.  
COMSOL can solve the fluid flow profile within and around complex geometries, so an 
initial simplified model was created to determine the impact of channel geometry on fluid 
dynamics.  The experimental flow chamber  (6 cm × 1 cm × 0.0127 cm) was assumed to act as 
two infinite parallel plates, as the 78:1 width to height ratio exceeded the required 20:1 ratio for 
this assumption to be valid (Figure 3.1)  [111].  This simplified the model to a two dimensional 
flow with no variations perpendicular (z-direction) to the flow direction (x-direction).  The 
entrance length, defined as the distance required for a fully developed flow profile to arise, was 
calculated to determine if the flow could be assumed to be fully developed.  For inlet flow 
velocities set to achieve a wall shear stress from 1-122 dynes/cm
2
, the entrance length was less 
than 2.4% of the channel length (Figure 3.2).  
 
 
Figure 3.1: Flow chamber geometry for investigation of fluid dynamics. Inlet and outlet locations are 
perpendicular to the direction of developed flow in the chamber.  
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Figure 3.2: Variation of entrance length as a function of shear stress. 
 
 
Because this entrance length was sufficiently small, the model geometry was further simplified by 
relocating the inlet and outlet parallel to the overall flow chamber length (Figure 3.3).  This 
change in channel geometry allowed us to define the flow profile as fully developed and laminar 
(calculated Reynolds number ranged from 1-50, Figure 2.2) over the entire channel length 
(Equation 3.1). 
   (Equation 3.1) 
This equation establishes a parabolic flow profile throughout the channel where vmax is the 
maximum flow velocity, h is the channel height, and y is the distance from binding wall.  By 
setting the flow profile as a constant vector independent of the distance from the inlet in Figure 
3.3, the requirement to solve for the fluid flow profile prior to each BM-FGF2 binding reaction 
simulation was eliminated, thereby simplifying the simulation procedure and shortening model 
runtime.  
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Figure 3.3: Model schematic. Numbers represent boundaries, δ represents channel height. The internal 
blue area is the subdomain.  
 
Table 3.1: Model boundary conditions correlating to Figure 3.3. 
Boundary Type Condition Mathematical Definition 
1 Inlet Concentration  
2 Outlet Convective Flux  
3 
Top of channel, non-binding 
surface 
Insulation  
4 BM Binding Surface Convective Flux  
 
The fluid was defined as an incompressible Newtonian fluid with a no-slip boundary condition at 
the walls (Equation 3.1) and an outlet to atmospheric pressure (Figure 3.3).  Additionally, the 
channel was shortened from the experimental length of 6 cm to 1 cm for simulation purposes. 
Though the FGF2 boundary layer was dependent on channel length, we decided that this 
simplification was reasonable because the boundary layer size rapidly decreased with time and 
increasing shear stress.  
Convective and diffusive FGF2 transport were defined and coupled to the FGF2-HSPG 
binding reaction.  First, a constant FGF2 concentration was defined as the inlet boundary 
condition, and FGF2 remaining in solution after passing over the HSPG binding surface was 
transported out through the outlet (convective flux).  Next an insulation boundary condition was 
defined at the non-binding wall, which means that FGF2 was unable to transport into or through 
this surface.  Lastly, a convective flux boundary condition, where FGF2 flux was allowed 
perpendicular and into the binding surface, was assigned at the HSPG binding wall.  This allowed 
the FGF2-HSPG binding reaction to be defined, as described in the following section.  
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Convective and diffusive FGF2 transport was defined within the entire modeling subdomain 
using the standard convection-diffusion equation (Equation 3.2).  In this mass balance equation, 
the change in transported material concentration with time is balanced with diffusive and 
convective transport terms. A detailed drawing of boundary conditions and subdomain 
formulations can be found in Table 3.1 and Figure 3.3. 
 
  (Equation 3.2) 
 
After assigning necessary boundary conditions, the FGF2-HSPG reaction on the binding 
surface was coupled to the convective flux boundary condition.  Several simplifying assumptions 
were made to represent BM-FGF2 binding in the model.  BM HSPG distribution was assumed to 
be uniform, and FGF2 and HSPG were neither synthesized nor degraded during the reaction 
period.  Since experiments demonstrated that non-specific FGF2 binding to tubing and glass 
under flow was minimal, we neglected non-specific interactions and assumed FGF2 bound only 
to BM HSPG.  Finally, the binding reaction of FGF2 to BM HSPG was modeled as a reversible 
1:1 reaction governed by:  
    (Equation 3.3) 
Where FGFfr is the concentration of free FGF2 (mol/m
3
), HSPGfr is the concentration of free 
HSPG (mol/m
2
), kon is the association/on constant, and koff is the dissociation/off rate constant.  
The binding kinetics are then defined as  
 
  (Equation 3.4) 
 
Initial free FGF2 concentration was assigned using experimental parameters, while the HSPG 
binding site concentration was assigned according to the value calculated from the literature for 
BM FGF2 binding capacity [96].  The representative BM binding reaction (Equation 3.4) was 
defined at the bottom flow channel wall (Figure 3.3, boundary 4) and coupled via mass balance to 
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FGF2 bulk fluid transport.  Specifically, the binding reaction was defined using a one-
dimensional ―weak form‖ tangential partial differential equation.  This method couples FGF2 
transport tangential to the binding surface (left side of Equation 3.5) to the FGF2-HSPG reaction 
(the right side F of equation 3.5).   A complete list of modeling parameters is shown in Table 3.2.   
    (Equation 3.5) 
where  
   (Equation 3.6) 
 
 (Equation 3.7) 
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Table 3.2: Parameter values used in model development. 
Parameter Name Symbol Value/units Source 
Initial free FGF FGFfr 5.55 x 10
-7
 mol/m
3
 Exp.  Parameter 
Initial free HSPG on BM HSPGfr 4.48 x 10
-8
 mol/m
2
 [96] 
FGF-HSPG Complex concentration FGF-HSPG mol/m
2
 Exp.  Parameter 
Association of FGF2 and HSPG at 4°C kon,1 0.92 x 10
2
 µM
-1
min
-1
 [74] 
Association of FGF2 and HSPG at 23°C kon 1.17 x 10
2
 µM
-1
min
-1
 Exp.  Parameter 
Dissociation of FGF2 and HSPG at 4°C koff,1 0.095 min
-1
 [74] 
Dissociation of FGF2 and HSPG at 23°C koff 0.475 min
-1
 Exp.  Parameter 
Temperature T 296 K Exp.  Parameter 
Binding Surface Area SA 6 cm
2
 Exp.  Parameter 
Diffusion coefficient D 1.6 x 10
-10
 m
2
s
-1
 Exp.  Parameter 
Viscosity of water at 23°C µ 0.933 cP Exp.  Parameter 
Shear Rate  s
-1
 Exp.  Parameter 
Channel Height h 127 µm Exp.  Parameter 
Channel Length l 1 cm Exp.  Parameter 
 
 
 
Because all binding experiments were performed at room temperature (23°C), temperature-
dependent parameters (kon and koff) were adjusted from values at 4°C (kon,1/koff,1) using the 
Arrhenius equation: 
   (Equation 3.8) 
In this equation T1 is 277K, T2 is 296K, R is the universal gas constant (8.314 J/mol*K), and Ea is 
the activation energy of the FGF2-HSPG ―bond‖(8.49 kJ/mol, [109]).  The FGF2 diffusion 
coefficient in water at 23°C was calculated using the Stokes-Einstein equation: 
      (Equation 3.9) 
where kB is Boltzmann’s constant (1.3807×10
-23
 J/K), T is 296K, µ is water viscosity at 23 °C 
(0.933 cP), and σ is FGF2 radius in water (14.5 Å, [58]).  
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With the model fluid flow, diffusion, convection, and binding parameters now defined, 
the model was meshed to numerically solve the partial differential equations throughout the 
model geometry.  Over the majority of the model geometry COMSOL automatically defined the 
mesh to optimize mesh quality.  However, at the BM-FGF2 binding surface, the maximum mesh 
size was controlled to provide a high resolution of BM-FGF2 complex concentration.  The 
maximum element size was limited to 2 µm at the binding wall and the mesh element growth rate 
was adjusted.  The final mesh was chosen as the minimum number of elements that converged to 
a stable equilibrium solution (change of less than 0.1% when mesh element number was 
increased) with the shortest computation time.  A detailed list of the mesh parameters is shown in 
Table 3.3 and Figure 3.4 shows the relationship between mesh growth rate/the number of mesh 
elements and simulation runtime.  
Table 3.3: Final mesh parameters. 
Type triangular 
Degrees of freedom 249591 
Number of mesh elements 111785 
Number of mesh points 60331 
Number of boundary elements 8875 
Number of vertex elements 6 
Minimum element quality 0.6675 
Element area ratio 1.50E-08 
Maximum element size at binding wall 2 µm 
Element growth rate 1.3 
 
 
Figure 3.4: Model meshing optimization. 
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3.2.3 Model development with varying dissociation and non-varying association 
constants 
The initial model used association and dissociation constants that did not vary with shear 
stress, but results obtained with this model did not fit experimental data in which equilibrium 
BM-FGF2 binding varied with shear stress.  In the final model, koff was adjusted to fit a catch-slip 
binding profile.  Experimental data showed increased BM-FGF2 binding up to 25 dynes/cm
2
 
shear stress, followed by a decrease back to baseline as shear stress increased (Figure 2.4).  
Therefore koff was modified to decrease and then increase proportionally with shear stress.    Bell 
first explained the effect of an applied force on binding affinity as 
 
            (Equation 3.10, [84]) 
 
where F is the applied force, xa is the bond distance, kB is Boltzmann’s constant and T is absolute 
temperature.  To use this formula to adjust the rate constants, the force F must be determined and 
the bond distance known.  According to Goldman et al, a spherical particle under laminar flow 
while adhered to the flow chamber wall experiences a drag force F defined by:  
 
   (Equation 3.11, [112]) 
 
 
This formula cannot be directly applied to the force experienced by the FGF2-HSPG complex 
because it represents an ideal case of a spherical particle on a smooth surface.  FGF2 bound to 
BM HSPG has complicated geometry and FGF2 molecules are extremely small (14.5Å radius, 
[58]).  Since we believe that the change in BM-FGF2 binding with flow occurs through a 
mechanism different from the relatively simple effect of fluid flow imparting a drag force on an a 
large adhered particle, an alternative approach to adjusting koff as a function of shear stress was 
created. By assuming that association rate and total amount of free reactants (FGFfr and HSPGfr) 
did not change with time, and that at all shear stresses equilibrium (dFGF-HSPG/dt = 0) was 
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achieved after 1 hour (Figure 2.5), then Equation 3.4 could be rearranged to solve for koff  as a 
function of FGF-HSPGshear stress, FGFfr, and HSPGfr according to  
 
     (Equation 3.14) 
 
  FGF-HSPGshear stress was varied according to experimental results at each shear stress 
(Figure 2.4) with kon kept constant according to accepted values (Table 3.2).  Two separate 
relationships between shear stress and koff were created; one for shear stresses from 1-25 
dynes/cm
2
 (―catch‖ region) and the second for shear stresses from 50-122 dynes/cm2 (―slip‖ 
region).  25 dynes/cm
2
 was used as the switching point because this was where a binding peak 
was experimentally observed (Figure 2.4).   Following a similar form as the Bell model, a power 
law fit was applied to approximate a relationship between the experimental shear stress and koff.  
The calculated koff decreased up to 25 dynes/cm
2
 and then increased above 25 dynes/cm
2
 (Figure 
3.5).  The two separate relationships relating shear stress to koff are shown in Table 3.4.   
 
 
Figure 3.5: Relationship between experimentally measured dissociation rate (koff) and normalized shear 
stress. koff values were calculated using equation 7. Two separate power law fits of koff versus normalized 
shear stress where then applied. 
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Table 3.4: Calculation of binding constants using the catch-slip mechanism. 
Parameter Shear Stress (dynes/cm
2
) Formula/Value [units] 
kon,static 1 – 122 1.17 x 10
2
   [µM
-1
min
-1
] 
koff,static - 7.92 x 10
-3
   [s
-1
] 
koff 1 – 25  [s
-1
] 
koff 25 – 122  [s
-1
] 
 
 
3.2.4 Variation of FGF2, HSPG, and binding constants in the model: sensitivity analysis 
compared to experimental work 
Lastly, the model was used to determine the effect of HSPG concentration and 
experimental variability on BM-FGF2 binding calculations. kon, koff, the BM HSPG amount, and 
the FGF2 solution concentration were adjusted in the model and compared to unpublished BM-
FGF2 binding results. These experiments demonstrated that BM HSPG decreased as culture 
glucose concentration was increased (Figure 3.6A).  However, kon, koff, and equilibrium binding 
capacity did not change significantly as a function of culture glucose concentration (Figure 3.6B).  
 
Figure 4.6: (A) BM HSPG production by EC cultured in normal, medium, and high glucose. (B) FGF2 
binding capacity to basement membrane grown in 5, 17.5, and 30 mM glucose media. Experiments were 
run statically with 5 ng/mL FGF2. 
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3.3 Results 
3.3.1 Binding kinetics control BM- FGF2 time to equilibrium at low shear stresses while 
at high shear stresses convective transport dominates   
The initial model with constant FGF2-HSPG association and dissociation constants (kon, 
koff) was used to examine the effect of flow rate and shear stress on BM-FGF2 pre-equilibrium 
binding.  Time was held constant at 20 minutes, and fluid flow rate was varied to achieve shear 
stresses ranging from 1-122 dynes/cm
2
.  FGF2 boundary layer thickness decreased with 
increasing shear stress (Figure 3.7).  Specifically, at the flow chamber exit, the boundary layer 
thickness was 26, 11.1, 6.7, and 4.3 µm for shear stresses of 1, 12, 25, and 50 dynes/cm
2
 
respectively (Figure 3.7).  For all shear stresses and time points the boundary layer thickness 
grew from inlet to outlet as the FGF2 transport gradient developed over the chamber length 
(Figure 3.7).  At high flow rates, convective transport rapidly conveyed FGF2 to the reactive 
binding surface even as it was depleted from the fluid due to surface binding.  However, at low 
flow rates, binding kinetics dominated over convection, which resulted in a thicker FGF2 
depleted boundary layer.  Similarly, binding equilibrium was established earlier at higher flow 
rates (Figure 3.8).   
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Figure 3.7: Prior to equilibrium, shear stress affected FGF2 convective transport to the binding surface. 
FGF2 boundary layer thickness decreased with increasing shear stress 20 minutes after simulated flow 
initiation. Dimensions: Length 1 cm, height 63.5 µm (half the flow channel height). 
 
 
Figure 3.8: Convective transport governed time to equilibrium binding.  Normalized FGF2 concentration 
increased with time for each shear stress and the greater the flow rate the more quickly equilibrium was 
established. All concentrations normalized to the FGF2-HSPG concentration after 120 minutes of flow. 
Equilibrium was not necessarily achieved at all shear stresses after 120 minutes (see Figure 3.14). 
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When time was varied and shear stress was held constant, FGF2 boundary layer thickness 
decreased with increasing time.  At 25 dynes/cm
2
 shear stress, the FGF2 concentration at the wall 
after 60 minutes of flow increased to 5.56 x 10
-7
 mol/m
3
 (10 ng/mL), a nearly threefold change 
compared to 2 minutes of flow (Figure 3.9).  All simulated shear stresses showed a similar trend, 
demonstrating that the FGF2 depleted boundary layer thickness decreased as BM-FGF2 binding 
reached equilibrium.   
 
 
Figure 3.9: Prior to equilibrium, shear stress affected FGF2 convective transport to the binding surface. 
As simulated flow time increased, boundary layer thickness decreased. Graph depicts 25 dynes/cm
2
 shear 
stress at channel midpoint. 
 
 
3.3.2 Model simulations are sensitive to modeling parameters 
 The effect of available FGF2 and HSPG binding site concentration was investigated 
using constant association and dissociation constants.  When FGF2 in solution was increased 
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from 0 to 5000 ng/mL, BM-FGF2 complex concentration increased up to a peak of 7.8 ng/cm
2
 at 
1,000 ng/mL FGF2, after which it remained constant (Figure 3.10).  Furthermore, the time 
required to reach equilibrium decreased dramatically as FGF2 concentration increased.  At FGF2 
concentrations of 250 and 5,000 ng/mL, 20 minutes and only 34 seconds were required to reach 
equilibrium binding, respectively, at 25 dynes/cm
2
 shear stress (Figure 3.11).  Increasing binding 
surface HSPG concentration caused FGF2-HSPG complex concentration to increase linearly. 
Unlike varying FGF2 concentration in solution, FGF2-HSPG binding did not saturate with 
increasing HSPG binding sites (Figure 3.12). This result is expected as the incoming FGF2 
concentration has a constant value of 10 ng/mL, so the equilibrium concentration of FGF2-HSPG 
complexes will increase linearly with the concentration of HSPG (HSPG is the limiting reactant, 
Figure 3.12).  In contrast when FGF2 concentration is varied and HSPG concentration is held 
constant HSPG becomes the limiting reagent, as increasing FGF2 concentration will lead to 
HSPG saturation at some FGF2 concentration (Figure 3.10).  
 
 
Figure 3.10: BM-FGF2 binding varied with concentration of FGF2 in solution and saturated above 1000 
ng/mL FGF2. FGF2 in solution ranged from 1-5,000 ng/mL (10-50,000% of experimental concentration). 
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Figure 3.11: Time to equilibrium decreased as FGF2 concentration increased. Model run at 25 dynes/cm
2
. 
 
 
Figure 3.12:  BM-FGF2 binding varied linearly with concentration of HSPG on the binding surface. Model 
run at 25 dynes/cm
2
 with 10 ng/mL FGF2. 
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3.3.3 FGF2 equilibrium binding can be simulated by changing the dissociation rate 
constant in accordance with a catch-slip mechanism 
The computational model with constant BM FGF2 association and dissociation constants 
achieved equilibrium FGF2-HSPG binding of 964 pg/cm
2
 at all shear stress levels (Figure 3.10, 
solid line). The computational results were within 10% of experimental data for static conditions, 
suggesting that the model effectively simulated the experimental conditions. However, the ability 
of the computational model to predict experimental binding varied significantly with shear stress. 
At low shear stress (from 1-25 dynes/cm
2
) simulated BM-FGF2 binding was within 6.3 - 33.1% 
of experimentally measured values.  At higher shear stress this error increased up to 70%.  Since 
the computational model did not effectively simulate the variation in experimental FGF2 binding 
kinetics with shear stress, the model was improved by adjusting the dissociation constant (koff) 
according to a catch-slip mechanism (Section 3.2.3).  BM-FGF2 equilibrium binding simulations 
using variable koff closely matched experimental results (Figure 3.13, dotted line).  The percent 
error between experimental and computation results reduced to 1.5 - 22%.  The greatest 
improvement was observed at shear stresses of 50 dynes/cm
2
 and greater.  
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Figure 3.13: Fluid flow affected equilibrium binding through a catch-slip mechanism, whereas flow 
affected non-equilibrium binding through convective effects. Simulated BM-FGF2 binding kinetics were 
approximated to match experimental results by adjusting koff in agreement with a catch-slip binding 
mechanism.  
 
 
 
Simulated time to equilibrium decreased with increasing shear stress, independent of 
whether koff was held constant or varied with shear stress.  Specifically, shear stresses of 1, 25, and 
73 dynes/cm
2
 required 270, 105, and 90 minutes to reach equilibrium for constant static koff 
(Figure 3.14). Time to equilibrium using variable koff differed from static koff times by 15-29 
minutes.  As expected, the smallest difference was seen at 25 dynes/cm
2
, as static and variable koff 
were closest at this shear stress level.  These results suggest that time to equilibrium was 
governed by convective transport while equilibrium concentration depended on binding kinetics. 
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Figure 3.14: Fluid flow affected equilibrium binding through a catch-slip mechanism, whereas flow affects 
non-equilibrium binding through convective effects. Time to equilibrium varied with shear stress, but did 
not change with varying koff.  
 
 
3.3.4 Model simulations using experimentally determined FGF2, HSPG, and binding 
constants in the model  
Lastly, the model was used to explore why experimental data showed no change in BM-
FGF2 binding kinetics for BM cultured in high glucose, even though BM-HSPG concentration 
decreased (unpublished results, Section 3.2.4). When HSPG concentration was decreased with 
culture glucose level in accordance with experimental results, BM-FGF2 binding reached 
equilibrium at 29 and 138 pg/cm
2
 for low and high glucose, a 2.9-fold difference (Figure 3.15). 
This difference correlated with a 2.9-fold decrease in BM HSPG for BM produced by EC 
cultured in high vs. normal glucose.   
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Figure 3.15: BM-FGF2 binding to HSPG produced by EC cultured in normal (5 mM) and high (30 mM 
glucose) changed with HSPG content. Model run at a shear stress of 0.1 dynes/cm
2
 to simulate static 
binding experiments.  
 
 
 
When kon and koff were varied for the different BM produced in low and high glucose culture, 
FGF-BM binding equilibrated at 140 and 91 pg/cm
2
 (Figure 3.16).  In these simulations kon and 
koff values calculated from experimental data and including experimental error were used as model 
inputs.  When this error was accounted for in the model, the large and overlapping error bars in 
Figure 3.16 were produced.  The resulting lack of a significant difference may explain why 
Figure 3.16 more closely resembles Figure 3.6B than does Figure 3.15. 
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Figure 3.16: BM-FGF2 binding to HSPG produced by EC cultured in normal (5 mM) and high (30 mM 
glucose) did not change significantly with changing kon and koff values. Model run at a shear stress of 0.1 
dynes/cm
2
 to simulate static binding experiments.  
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3.4 Discussion 
FGF2 plays an important role in regulating vascular cell behavior both in healthy and 
pathological conditions.  FGF2 binding in the vasculature occurs under flow, so this flow was 
accounted for in both experiments (chapter 2) and our model (chapter 3).  In this chapter we 
showed that a computational model of BM-FGF2 binding with flow was developed by coupling 
convective and diffusive FGF2 transport to the HSPG-FGF2 binding reaction in the BM.  Model 
modification to include a catch-slip binding mechanism produced results which more closely 
resembled experimental results. 
The initial computational model used FGF2-HSPG association and dissociation constants 
(kon, koff) developed from static binding experiments.  However, this model did not accurately 
represent the changes in equilibrium BM-FGF2 binding with shear stress.  We therefore modified 
koff specifically to fit with our hypothesized catch-slip binding mechanism.  Ideally, we would 
have experimentally measured koff at different shear stresses by radioassay, but this was not 
possible due to equipment limitations.  We therefore used our equilibrium binding experimental 
data to adjust koff according to the catch-clip mechanism, where koff was proportional to the 
applied fluid shear stress and a cut-off was set for koff decrease and increase.  We initially used 
established relationships to determine binding constant changes with the applied force at each 
shear stress, but the small FGF2 diameter resulted in a drag force that was too small to change the 
dissociation constant significantly with flow.  This suggests that Goldman’s equation may break 
down when ligand geometry is sufficiently small, as it has only been used for micron sized 
particles such as cells or bubbles attached to a wall.  Furthermore, Bell’s equation is based on the 
postulate that force applied to a bond changes the bond energy and relates the dissociation 
constant to this force taken to the exponential power. However the relationship between our 
experimental dissociation constant and shear stress did not show an exponential trend, so we 
chose to use a power law fit over Bell’s equation.  We therefore developed an equation relating 
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the shear stress to experimental equilibrium binding data to adjust koff under static conditions 
(Table 3.1).  In the future, experimental measurement of changes in kon and koff of FGF2 to HPSG 
under applied force should be undertaken to compensate for limitations of current formulae.  
The computational model further suggests that time to equilibrium is governed by 
convective transport rather than binding kinetics, since simulated time to equilibrium 
proportionally decreased for increasing flow rate and the adjusted koff had little effect. The 
experimental time to equilibrium did not consistently fit with the computational results, possibly 
due to confounding experimental factors.  Specifically, the experimental time to equilibrium did 
not change between static and shear stress conditions.  This is likely related to our use of an 
orbital shaker for static samples.  Orbital rocking of static samples induced convective FGF2 
transport, while a purely static condition would rely on diffusive transport alone. Secondly, 
because convective transport and changing dissociation constants are coupled in our experimental 
measurements of flow effects on BM FGF2 binding, we cannot experimentally separate the 
effects of convection and applied force.  Finally, the large experimental variation may mask real 
differences in time to equilibrium.  
Model simulations varying the FGF2 amount available for binding and the HSPG binding 
site concentration support model utility.  As shown in Figure 3.10 the model saturated at a level 
of ~8 ng/cm
2
 with treatment of 2,500 ng/mL FGF2 or greater.  This agrees within an order of 
magnitude with published experimental data of BM-FGF2 binding capacity, which showed that 
BM-FGF2 binding reached equilibrium at about 25 ng/cm
2
 with 5000 ng/mL FGF2 applied [96]. 
The difference is likely attributed to a few effects, including that our model only allows binding 
of FGF2 to HSPG, while in experiments FGF2 may bind to areas other than HSPG.  Furthermore, 
FGF2 in the model does not degrade over time, while in experiments the applied FGF2 amount 
may be less than the expected amount due to degradation.  Such an effect has been shown in flow 
experiments where 200 and 75 pg/mL FGF2 degraded almost 50% after four hours of flow over 
60 
 
SMC [95].  These results suggest that the model may be useful in producing binding results 
which are more accurate but not entirely realistic as FGF2 degrades in vitro and likely in vivo as 
well.  Additionally, available FGF2 in the blood varies with time due to cellular uptake, BM 
deposition, and FGF2 degradation, while in our simulations the FGF2 amount was held constant.  
Unlike binding simulations which showed saturation at high FGF2 concentrations 
simulations run with varying HSPG concentration did not saturate (Figure 3.12). HSPG quantity 
deposited into the BM changes if EC are cultured in high glucose media or with sodium chlorate 
(unpublished results). Therefore, adjustment of HSPG concentration in the model was a relevant 
parameter to examine. When HSPG content was adjusted from 0.01-10,000% of experimental 
values, BM-FGF2 binding increased accordingly. This result occurred because in the model the 
FGF2 concentration at the inlet does not change over time (10 ng/mL) regardless of FGF2 lost to 
previous binding.  In experiments, however, the 10 ng/mL FGF2 solution was recirculated and 
not replenished over time like occurred in the model.  About 6% of the total FGF2 in solution was 
bound to the BM, a small but significant amount.  Therefore future model updates should include 
adjustment of inlet FGF2 due to FGF2 depleted from the solution by HSPG binding.    
Model simulations were also shown to be sensitive to experimentally measured BM 
HSPG content and BM-FGF2 binding constants.  BM HSPG decreased with increasing culture 
glucose content, however no experimental decrease in BM-FGF2 binding was observed.  In 
contrast, BM-FGF2 binding simulations showed a significant change in BM-FGF2 binding with 
changes in BM HSPG (Figure 3.15). This could be related to model limitations, including the 
assumption that all BM HSPG are available for FGF2 binding. When kon and koff were changed 
based on experimental results, including the experimental error in kon and koff calculations, the 
change in BM-FGF2 binding with BM HSPG content was no longer significant (Figure 3.16). 
Thus future versions of the model should take into account changes in HSPG binding availability, 
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and model results must be interpreted with an understanding of experimental error in model input 
parameters.  
Our model was similar to the existing computational model of EC FGF2 binding with 
fluid flow, mass transport, and binding kinetics in that we also used FGF2 binding kinetic 
parameters based on experimental measurements from static models [85].  However, their model 
analyzed only low flow rates (shear stresses of 0.01-0.1 dynes/cm
2
) as well as a low FGF2 
concentration (0.0555 nM), which are both 1000-fold smaller than those used in our model.  Shen 
et al examined only cell-FGF2 binding rather than BM-FGF2 binding, and their model addresses 
only transient FGF2 binding prior to equilibrium.  Since they did not validate their computational 
model with experimental data, they did not change their binding constants with flow.  Despite 
these differences, both models show position and time dependent binding prior to equilibrium, 
with the greatest concentration of FGF2-HSPG complexes closest to the inlet at early time points 
while at later time points the distribution becomes more spatially uniform.  
The computational model of FGF2 convective and diffusive transport and BM-FGF2 
binding at the surface under flow provided an effective first approximation, but simplifying 
assumptions including a laminar flow profile, infinitely thin BM, and homogenously distributed 
HSPG, could limit model accuracy.  While the flow profile was fully developed and laminar 
across the entire flow chamber, local anomalies at the BM surface may occur because the BM has 
an irregular geometry.  These nanoscale flow disturbances may be significant for FGF2 transport 
near the BM.  If HSPG are not homogeneously dispersed in the BM, such as located nearer to the 
apical side of the BM or ―hidden‖ basally within the BM, an interesting effect on BM-FGF2 
complex distribution may occur. If the majority of HSPG were on the surface of the BM, 
simulations would be governed by convective transport to the BM surface.  However, if HSPG 
were located basally in the BM, transport normal to the flow direction within the BM would be 
required.  Diffusion through the BM has been shown to be significant for FGF2 transport through 
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the BM and may also be significant in our system [58].  It is possible that for such a case, FGF2 
binding to HSPG would be minimal at very high flow rates where strong convection restricts 
transport through the BM to HSPG.  HSPG distribution may also vary across the flow channel 
length and width due to cellular production of BM, isolation methods, or channel assembly and 
would further complicate BM simulation.  Therefore in the future, more advanced models will 
incorporate the BM geometric and biochemical complexity.  
In conclusion, we developed a computational model of BM-FGF2 binding with flow 
which included a catch-slip binding mechanism.  The model was sensitive to input parameters 
including FGF2 and HSPG concentrations as well as binding constants.  Computational results 
closely resembled experimental results, but also showed how experimental error can lead to 
variation in simulations.     
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4. ENDOTHELIAL AND VASCULAR SMOOTH MUSCLE CELL FGF2 
RESPONSE IS AFFECTED BY HIGH GLUCOSE AND COLLAGEN 
GLYCATION 
 
 
4.1 Introduction  
In chapters two and three we showed that EC BM-FGF2 binding changes under flow 
perhaps by a catch-slip mechanism, and we developed a computational model to investigate 
convective and diffusive binding effects.  This change in FGF2 binding and release may affect 
EC and SMC.  EC and SMC dysfunction in diabetes contributes to development of 
atherosclerosis and restenosis as well as microvascular and macrovascular complications.  FGF2 
may be an important factor in these processes, characterized by alterations in cell proliferation, 
migration, and survival.  However, the effect of FGF2 on EC and SMC in hyperglycemic culture 
is not well described.  
EC and SMC behavior changes in hyperglycemia in vitro and in vivo.  EC proliferate less 
in high glucose culture [113-114], while the effect of glucose on SMC proliferation has been 
debated in the literature.  In vitro experiments show conflicting results as some have shown high 
glucose increases SMC proliferation [115-116] while others that proliferation does not change 
[12].  This is supported by results showing ex vivo proliferation of isolated SMC from diabetic 
animals and healthy pigs does not change in high glucose [117].  High glucose also increases EC 
apoptosis both in vitro [118-121] and in vivo [122].  Interestingly, high glucose inhibits SMC 
apoptosis through the up-regulation of anti-apoptotic proteins [123-124].  
BM collagen glycation occurs in high glucose and may play a role in vascular 
dysfunction.  EC cultured on glycated collagen become apoptotic, proliferate less, have a reduced 
adhesion capacity, and experience early senescence [125-126].  Additionally EC migration 
decreases on glycated collagen, suggesting inhibition of angiogenesis [127].  Bovine aortic EC 
adhere to and spread less on glycated collagen than collagen [128].  Other work indicates that 
human umbilical vein EC proliferation on glycated collagen depends on seeding density [129].  In 
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contrast, human SMC attachment does not vary significantly on collagen or glycated collagen 
[130].  After attachment SMC proliferation is decreased on collagen, an effect that is reversed 
with glycated collagen [130].   
FGF2 plays an important role in regulating vascular cell behavior.  FGF2 induces EC 
proliferation, migration, and differentiation [64-65], as well as SMC proliferation and migration 
in vivo [31, 66-68].  FGF2 is highly present in the diabetic environment since both hyperglycemia 
and mechanical damage lead to increased EC FGF2 release and FGF2 BM storage [40-42].  EC 
FGF2 release increases following TNFα treatment in high glucose [131].  When cultured in high 
glucose medium, both EC FGF2 release and permeability increases [43].  Despite the knowledge 
that available FGF2 level increases in hyperglycemia, the effect of FGF2 on EC and SMC has not 
been studied in high glucose in vitro. 
FGF2 activates the ERK pathway, which is important for EC and SMC proliferation and 
migration. Activation of ERK enhances proliferation and migration, with ERK inhibition causing 
decreased cell number [114].  FGF2 binding to FGFR promotes autophosphorylation of tyrosine 
amino acids on intracellular FGFR segments, which facilitates binding to the G-protein GRB-2 
[132].  This in turn activates a signaling cascade including Ras, Raf, and MEK, and culminates in 
ERK phosphorylation [132].  pERK then enters the nucleus and phophorylates Jun which binds 
with Fos, forming the transcription factor AP-1 (activator protein-1) [72]. AP-1 induces 
transcription of various proteins related to cellular proliferation and migration.  See Figure 4.1 for 
a schematic of ERK signaling. 
FGF2 also activates the Akt pathway, which is important in regulating cell survival with 
activation of Akt having an anti-apoptotic affect.  FGF2 binding to FGFR tyrosine kinase 
activates PI3K (phosphoinositide 3-kinase) which leads to Akt phosphorylation [133].  pAkt then 
inhibits caspase-9, BAD (Bcl-2-associated death promoter), and ASK-1 (apoptosis signal-
regulating kinase 1), which are proteins involved  apoptosis, thereby enhancing cell survival [73].  
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EC cultured with increasing glucose concentration led to a decrease in pAkt levels, decreased 
proliferation, and increased apoptosis [134-135].  See Figure 4.1 for a schematic of Akt signaling.  
Though the role of FGF2-activated ERK and Akt signaling is well characterized, the response to 
FGF2 for EC and SMC grown in high glucose or on glycated collagen is not well studied. 
 
 
 
Figure 4.1: FGF2 activates the ERK and Akt pathways. Created by consulting[113-114].  
 
 
FGF2 may be implicated in vascular cell dysfunction in hyperglycemic conditions. 
Because of the role of high glucose and glycated collagen in diabetic pathologies, the FGF2 affect 
on EC and SMC proliferation, death, and signaling were investigated.  We hypothesized that EC 
and SMC proliferation and survival in response to FGF2 would be inhibited in hyperglycemic 
culture, leading to decreased cell growth and increased cell death.  We now show that vascular 
cell behavior in response to FGF2 changes in diabetic culture conditions through alteration of the 
Akt survival pathway on glycated collagen. 
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4.2 Methods 
4.2.1 Cell culture 
EC were isolated from porcine aortae by collagenase dispersion [94].  For SMC isolation, 
the tunica media was separated from an aortic section and cultured statically.  SMC that migrated 
out of the tissue were collected and expanded for experiments [136].  EC and SMC were 
maintained in DMEM as described, supplemented with 5% and 10% FBS for EC and SMC, 
respectively.  Cultures were fed every 2 days and passaged using 0.025% trypsin-EDTA 
(Invitrogen).  Cells in all experiments were between passages 4 and 9. 
 
4.2.2 EC and SMC proliferation in hyperglycemic conditions 
For proliferation studies EC or SMC were seeded at 10,000 cells/well (2.6×10
3
 cells/cm
2
) 
in 12 well plates.  To investigate FGF2 effects on cell proliferation in high glucose, EC and SMC 
were cultured in normal glucose (5 mM) or high glucose (30 mM) supplemented medium.  
Mannitol (25 mM) served as an osmotic control for high glucose medium.  To investigate FGF2 
effects on cell proliferation on glycated collagen, EC and SMC were grown in normal glucose 
medium on bare tissue culture plastic (TCP), collagen coated (10 μg/mL or 5.26 µg/cm2), or 
glycated collagen coated (10 μg/mL or 5.26 µg/cm2) wells.  At days 1, 3, and 5, cells were given 
fresh medium and 0, 2.5, 5, or 10 ng/mL FGF2 was added.  On days 1, 3, 5, and 7, the cells were 
trypsinized and counted using a Coulter counter (Beckman Coulter).  
Type I collagen was glycated using the Maillard glycation reaction.  100 µg/mL collagen 
was incubated with 500 mM D-glucose-6-phosphate sodium salt in PBS at 37°C for four weeks. 
Collagen glycation was measured by gel electrophoresis and autofluorescence.  Collagen was 
prepared for electrophoresis by 1:1 digestion for 30 minutes at 37°C in a 0.2% collagenase in 
PBS.  Gels were then stained with Coomassie Blue and imaged by white light illumination via a 
scanner.  Collagen glycation decreased the ability of collagenase to cleave the protein into smaller 
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fragments, thus validating collagen glycation.  Additionally, normal and glycated collagen were 
excited at 370 nm, and collagen emission was collected from 350-550nm at 2nm increments. 
After 4 weeks of glycation the glycated sample emitted a higher glycation-characteristic auto-
fluorescence than native collagen samples, correlating with previous work verifying collagen 
glycation by this method [137]. 
 
4.2.3 EC and SMC Signaling on glycated collagen 
Western blots were conducted to measure EC and SMC FGF2 signaling.  Cells were 
seeded at 250,000 cells/well (2.6×10
4
 cells/cm
2
) in 6 well plates and cultured for 4 days in the 
medium and coating conditions described previously.  Cells were then starved for 24 hours using 
serum-free medium (EC) or 1% BSA in serum-free medium (SMC).  Starved cells were given 50 
ng/mL FGF2 for 10 (EC) or 15 minutes (SMC) in serum-free medium, and cell extract was 
collected using a protease-inhibited lysis buffer (20 mM Tris, 150 mM NaCl, 1% Triton X-100, 
0.1% SDS, 10% glycerol, 2mM EDTA, 2mM Na3VO4, 2mM PMSF, 50mM NaF, and complete 
protease inhibitor (Roche) in distilled water, pH 7.5).  Extracted protein was normalized using the 
Quanti-iT kit (Invitrogen) or BCA assay (Sigma).  Protein samples were run on a 4-12% Bis-Tris 
gel (Invitrogen), transferred to a PVDF membrane (Invitrogen), and blocked for 1 hour with non-
fat dry milk (Biorad).  Membranes were incubated overnight at 4°C with anti-ERK, anti-phospho-
ERK, anti-Akt, or anti-phospho-Akt antibodies (1:1000 or 1:300 dilution, Cell Signaling).  
Horseradish-peroxidase conjugated secondary antibodies (1:2000 dilution, Santa Cruz) and a 
chemiluminescence kit (Perkin Elmer) were used to visualize bands.  Protein level was measured 
by densitometry analysis using a Fluorchem SP Imaging System (Alpha Innotech).  ERK and Akt 
levels were analyzed to ensure equal protein loading for pERK and pAkt Western blot 
interpretation.  
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4.2.4 Statistical Analysis 
Statistical analyses were conducted using the Microsoft Excel Data Anaylsis ToolPak.  
Data is presented graphically as mean ± standard deviation.  Comparisons between two groups 
were analyzed by Student’s t-test, while comparisons between more than two groups were 
analyzed by ANOVA.  A value of p < 0.05 was considered statistically significant and shown in 
figures with an asterisk (*) or pound sign (#). 
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4.3 Results 
4.3.1 EC and SMC attachment did not change in high glucose or on glycated collagen  
 EC and SMC attachment in high glucose and on glycated collagen was monitored as 
preliminary work in understanding cell behavior in hyperglycemic conditions.  After 1 day no 
difference in EC number was observed for cells grown in high glucose (Figure 4.2A) or on 
glycated collagen (Figure 4.3B).  SMC adhesion also did not depend on glucose or coating 
condition (Figures 4.2B, 4.3B).  Therefore, cell number on days 3, 5, and 7 for both cell types and 
all conditions were normalized to day 1 counts to determine the fold increase in cell number.   
 
 
 
Figure 4.2: EC attachment did not vary with medium glucose level. Cell number measured 24 hours after 
seeding. Cell number measured 24 hours after seeding. TCP stands for tissue culture plastic.  
 
 
Figure 4.3: SMC attachment did not vary with medium glucose level. Cell number measured 24 hours after 
seeding. TCP stands for tissue culture plastic.  
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4.3.2 EC and SMC proliferation changed in hyperglycemic conditions 
EC and SMC proliferation in high glucose and on glycated collagen was also examined. 
EC proliferation decreased 18% in high glucose medium after 5 days compared to cells cultured 
in normal glucose medium (p = 0.027 , Figure 4.4A). However, this difference was not present at 
day 3 and disappeared by day 7. SMC did not show a significant difference in proliferation for 
different medium glucose content at any time point (Figure 4.4B).  
 
 
 
Figure 4.4: EC (A) and SMC (B) proliferation did not vary with glucose concentration. EC and SMC were 
cultured for 7 days with 5 mM (normal glucose), 30 mM (high glucose), or 5 mM glucose and 25 mM 
mannitol (mannitol).  Cell number at days 3, 5, and 7 was normalized to day 1 cell counts.  
 
 
 
EC and SMC proliferation varied with collagen coating condition.  20% more EC were 
present on glycated collagen than on collagen after 5 days (p = 3.5×10
-3
), though there was no 
difference in proliferation between TCP and collagen (Figure 4.5A).  By day 7 this difference in 
EC number disappeared likely due to EC reaching confluence.  After 3 days there was no effect 
of coating condition on SMC proliferation (Figure 4.5B).  By day 5, 62% and 20% more SMC 
were on collagen and glycated collagen than TCP, respectively (p = 3×10
-6
 and 6.7×10
-3
).  This 
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difference was less profound at day 7 with 34% more SMC on collagen than TCP (p = 1.5×10
-3
) 
and no difference between glycated collagen and TCP.   
 
 
 Figure 4.5: EC (A) and SMC (B) proliferation varied with coating condition.  Cell number measured 24 
hours after seeding. Cell number at days 3, 5, and 7 was normalized to day 1 cell counts.  
 
 
4.3.3 EC and SMC treated with FGF2 increased proliferation 
EC and SMC proliferation increased significantly when cells were treated with FGF2 in 
normal glucose medium. EC reached confluence after 5 days of culture with FGF2 treatment, 
showing an almost twofold increase over EC cultured without FGF2 (Figure 4.6A).  EC number 
increased 26 and 19-fold from day 1 with and without FGF2 after culture for 7 days, respectively. 
The increase in EC proliferation due to FGF2 treatment was not dependent on the FGF2 
concentration added, suggesting that cells were saturated at FGF2 concentrations above 2.5 
ng/mL.   
FGF2 also increased SMC proliferation.  After 5 days of culture, SMC number increased 
from 20-fold to between 32 and 36-fold when cultured with FGF2 (Figure 4.6B).  SMC 
proliferation rate did not vary significantly between FGF2 concentrations of 2.5, 5, or 10 ng/mL, 
72 
 
and SMC proliferation increased up to day 7, suggesting that cells may be saturated with FGF2 at 
2.5 ng/mL. 
 
 
 
 
 
Figure 4.6: EC and proliferation increased with FGF2 stimulation. (A) EC were cultured in DMEM (5% 
FBS, 5 mM glucose) for 7 days. (B) SMC were cultured in DMEM (10% FBS, 5 mM glucose) for 7 days.  
Cells were treated with 0, 2.5, 5, or 10 ng/mL FGF2 on days 1, 3, 5, and 7. Cell number at days 3, 5, and 7 
was normalized to day 1 cell counts.  
 
 
EC and SMC proliferation in response to FGF2 in high glucose and on glycated collagen 
was also examined.  FGF2 treatment increased EC and SMC proliferation compared to non-
stimulated cells for all medium conditions.  32% and 86% more EC and SMC were present when 
treated with FGF2 on day 7 compared to non-stimulated cells in normal glucose medium at day 7 
(p = 3×10
-3
 and 4.6×10
-5
, Figure 4.7).  By day 5 FGF2-treated EC reached confluence as EC 
number did not vary between days 5 and 7(Figure 4.7A).  FGF2-treated SMC in contrast 
continued to proliferate beyond day 5 and did not show development of a quiescent state (Figure 
4.7B).  Neither EC nor SMC showed a significant difference in proliferation for different medium 
glucose content.  
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Figure 4.7: FGF2 stimulated EC (A) and SMC (B) proliferation did not vary with glucose concentration.  
EC and SMC were cultured for 7 days with 5 mM (normal glucose), 30 mM (high glucose), or 5 mM 
glucose and 25 mM mannitol (mannitol).  Cell number at days 3, 5, and 7 was normalized to day 1 cell 
counts. Cells were treated with 0 or 10 ng/mL FGF2 on days 1, 3, 5, and 7.  Cell number at days 3, 5, and 
7 was normalized to day 1 cell counts. EXP 1, 14. 
 
 
FGF2 stimulated EC and SMC proliferation varied with collagen coating condition.  
FGF2 treatment significantly increased EC and SMC proliferation compared to non-treated cells 
at each day (Figure 4.8).  60% and 100% more EC and SMC were present when treated with 
FGF2 on day 7 compared to non-stimulated cells on bare TCP at day 7 (p = 2.7×10
-4
, 2.9×10
-6
, 
Figure 4.8).  After 5 and 7 days of culture there was 20% and 16% more EC on glycated collagen 
than on collagen with FGF2 treatment (p = 0.015 and 6.7×10
-3
, Figure 4.8A).  There was not a 
significant change in cell number between days 5 and 7 suggesting EC had reached confluence. 
 FGF2-treated SMC grew most rapidly on collagen, with no difference between SMC on 
TCP or glycated collagen (Figure 4.8B).  After 3 days there was a 13% increase in SMC 
proliferation on collagen substrates with respect to glycated collagen when treated with FGF2 (p 
= 6.9×10
-3
).  This difference was less profound at day 5 with 6% more SMC on collagen than 
glycated collagen and TCP (p = 0.025 and 0.006), and had disappeared by day 7.   
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Figure 4.8: EC (A) and SMC (B) proliferation varied with coating condition.  Cell number measured 24 
hours after seeding. Cells were treated with 0 or 10 ng/mL FGF2.  Cell number at days 3, 5, and 7 was 
normalized to day 1 cell counts.  
 
 
4.3.4 EC and SMC treated with FGF2 changed pERK signaling on glycated collagen 
The effect of hyperglycemia on proliferation-related ERK signaling was quantified by 
Western blot.  FGF2 timing tests were performed to determine the optimal EC FGF2 treatment 
time, and showed that pERK levels peaked with 10 minutes of FGF2 application (Figure 4.9). 
Therefore, for all subsequent EC signaling assays EC were treated with FGF2 for 10 minutes.  
 
 
 
Figure 4.9: EC ERK phosphorylation peaked after 10 minutes of FGF2 treatment. Cells were treated with 
10 ng/mL FGF2. 
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Signaling in the ERK pathway was then investigated for EC cultured on glycated 
collagen.  pERK levels were minimal without FGF2 treatment but following FGF2 treatment 
pERK levels increased 2.25-2.4 fold from non-treated TCP controls (Figure 4.10). pERK 
signaling was independent of substrate coating condition as little difference in pERK was 
observed between TCP, collagen, and glycated collagen.  
 
 
 
Figure 4.10: pERK signaling of EC grown on tissue culture plastic, collagen, or glycated collagen. Note: 
For pERK the bare lane was loaded with 2x too much protein; therefore was analyzed by dividing the band 
intensity by 2. Signaling normalized to non-stimulated tissue culture plastic.  
 
 
SMC intracellular signaling was also examined.  Preliminary work investigating optimal 
SMC starvation showed pERK signaling was minimized with 1% BSA – supplemented medium 
for 1 hour (Figure 4.11).  FGF2 timing tests indicated that pERK levels peaked with 15 minutes 
of FGF2 application (Figure 4.12); for all subsequent SMC signaling assays SMC were treated 
with FGF2 for 15 minutes.  
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Figure 4.11: ERK phosphorylation was minimized with 1% BSA treatment for 1 day. Samples were not 
treated with FGF2.  
 
 
Figure 4.12: ERK phosphorylation peaked after 15 minutes of FGF2 treatment. Cells were treated with 10 
ng/mL FGF2. 
 
 
Following SMC starvation conditions optimization, SMC ERK signaling on collagen and 
glycated collagen was performed.  FGF2 treated SMC ERK levels varied slightly, with the largest 
variation seen for glycated collagen (Figure 4.13).  pERK signaling was minimal without FGF2 
treatment and did not vary with substrate coating.  FGF2 treatment increased pERK levels 
slightly, with the largest increase seen with SMC grown on TCP (Figure 4.13).  pERK quantity in 
FGF2-stimulated SMC grown on collagen and glycated collagen was lower than TCP but did not 
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vary between collagen and glycated collagen.  Basal ERK signaling was uniform across TCP, 
collagen, and glycated collagen suggesting equal protein loading. 
 
 
 
Figure 4.13: pERK signaling of SMC grown on tissue culture plastic, collagen, or glycated collagen. 
Signaling normalized to non-stimulated tissue culture plastic.  
 
 
 
 
4.3.5 EC treated with FGF2 changed pAkt signaling on glycated collagen  
Akt signaling is related to cell survival and may change in hyperglycemia.  EC Akt 
signaling was also measured.  pAkt signaling was minimal without FGF2 treatment but FGF2 
treatment increased pAkt levels (Figure 4.14).  pAkt quantity nearly tripled with FGF2 treatment 
for EC cultured on TCP and collagen compared to non-stimulated TCP controls.  However, EC 
on glycated collagen increased pAkt levels only 1.25-fold.  Akt levels were uniform across all 
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substrate coating conditions and did not change with FGF2 treatment, suggesting equal protein 
loading (Figure 4.14).   
 
 
 
Figure 4.14: pAkt signaling of EC grown on tissue culture plastic, collagen, or glycated collagen. 
Signaling normalized to non-stimulated tissue culture plastic.  
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4.4 Discussion 
EC and SMC dysfunction in hyperglycemic conditions may be related to FGF2.  We have 
previously shown that BM-FGF2 binding changes with shear stress.  We now show that this BM-
bound FGF2 differentially affects EC and SMC under hyperglycemic conditions.  Our results 
suggest FGF2 cannot rescue EC from death via the Akt pathway in hyperglycemia while the ERK 
pathway is functional. Specifically, FGF2 affects EC behavior in hyperglycemia through 
alteration of the Akt survival pathway on glycated collagen.  Proliferation-related pERK signaling 
did not change when cells were cultured in hyperglycemic conditions.  EC and SMC FGF2 
treatment increased cell proliferation compared to non-stimulated controls but there was no 
difference in EC or SMC proliferation as a function of glucose concentration when treated with 
FGF2.  EC stimulated with FGF2 proliferated less on collagen than glycated collagen but SMC 
proliferation did not change with coating condition.  
EC and SMC dysfunctional response to FGF2 may be important in vivo and contribute to 
the development of vascular disease.  If EC are unable to be rescued from death by FGF2, the 
endothelial barrier function may be compromised and the vessel may become pro-thrombotic. 
However, enhanced EC proliferation rate could increase to maintain a viable EC layer.  SMC 
increased proliferation on glycated collagen could in vivo be a factor in intimal hyperplasia. 
Together with other changes in the vasculature this FGF2-related dysfunction may contribute to 
atherogenesis and restenosis.  
EC and SMC attachment did not change with medium glucose level or collagen 
glycation.  Our results are further supported by consistent EC spreading on native or glycated 
collagen (unpublished data) and research showing that EC attachment does not change with high 
glucose culture [138], though EC cultured in high glucose medium overexpress integrins. 
However, the literature indicates that BM collagen glycation may reduce EC adhesion capacity as 
EC adhere to and spread less on glycated collagen than collagen [126, 128].  This difference from 
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our results may be due to difference in seeding density, which has been shown to be important for 
HUVEC proliferation [129]. We sparsely seeded cells (2.6×10
3
 cells/cm
2
) which may explain 
why we did not observe any variation in EC attachment and significant proliferation differences 
occurred only after 5 days.  Previous work has shown that human SMC attachment does not vary 
significantly on collagen or glycated collagen after 1 day [130].  Their collagen and glycated 
collagen density was similar to ours (7.89 µg/cm
2
 compared to 5.26 µg/cm
2
) reinforcing the 
validity of our results.  Interestingly, they quantified attachment by measuring the number of non-
adhered SMC; this method may be more accurate than our method of counting adhered cells as 
non-adhered SMC are unable to proliferate.  
We did not observe a difference in cell proliferation in high glucose culture both with and 
without FGF2.  This is in contrast to other work, which has shown that EC proliferate less in high 
glucose culture [113-114], though the effect of FGF2 was not examined. This apparent 
inconsistency may be related to the time in hyperglycemic culture conditions or cell source. In 
our experiments, SMC proliferation did not change with glucose level, which agrees with the 
literature.  Our proliferation measurements also relied on cell counts, which cannot distinguish 
between adherent healthy and adherent early-apoptotic cells, incomplete cell removal, and 
seeding density differences among wells.  Because pERK increases cell proliferation at the same 
time pAkt (and thus cell survival) is decreased, the overall effect on cell behavior may not be 
clear using the proliferation assay. 
 EC proliferation on glycated collagen varied only at day 5 of culture with more EC on 
glycated collagen than collagen. SMC proliferated more slowly on glycated collagen than 
collagen. FGF2 stimulated SMC proliferation did not change with coating condition, but EC 
stimulated with FGF2 proliferated less on collagen than glycated collagen. EC cultured on 
glycated collagen have previously been shown to proliferate less than EC under normal 
conditions [125-126] which disagrees with our increase in EC proliferation on glycated collagen. 
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SMC proliferation has been shown to decrease on collagen and be reversed with glycated 
collagen [130], which is in contrast to results.  These differences could be due to differences in 
cell source, extent of collagen glycation, or collagen concentration.  However proliferation results 
may be related to our attachment results, which showed no change in EC or SMC attachment on 
glycated collagen, or seeding density [129].   
 pAkt signaling decreased for EC on glycated collagen compared to collagen suggesting 
that FGF2 have decreased ability to promote EC survival through the Akt pathway in 
hyperglycemic culture.  As a survival pathway, this decrease in pAkt signaling would lead to an 
increase in cell death.  Our observations of decreased pAkt signaling on glycated collagen is 
supported by previous research showing EC cultured on glycated collagen become apoptotic 
[125-126].  However these experiments do not investigate the role of FGF2 in these processes.  In 
contrast, proliferation-related pERK signaling did not change when cells were cultured in 
hyperglycemic conditions. This lack of change in SMC pERK signaling is reflected in our 
proliferation experiments which showed that FGF2 stimulated SMC proliferation did not change 
with coating condition.  ERK signaling results agree with a prior study which showed no change 
in ERK or Akt signaling for SMC from the saphenous vein of diabetic patients compared to non-
diabetic patients [117].  Together, our results suggest that the ERK pathway is functional when 
activated by FGF2 but FGF2 cannot rescue EC from death via the Akt pathway in hyperglycemia. 
The ERK and Akt pathways are activated by FGF2 and can cross-talk in the cell through 
Raf, with pAkt inhibiting formation of Raf and therefore leading to a decrease in Erk activation 
[139].  It therefore may be difficult to see changes in cell behavior through non-specific assays 
such as the proliferation assay. The more sensitive procedure of measuring protein by Western 
blot did show a change in Akt signaling for EC, but no difference in ERK signaling for EC or 
SMC.  For the proliferation assay the total number of adhered cells was counted; therefore cells in 
early apoptosis would be counted as proliferating.  Additionally because we only measured the 
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change in pERK and pAkt we cannot say at what level of the signaling cascade FGF2 signaling in 
hyperglycemia changes.  Therefore, future experiments should measure protein levels up and 
downstream of ERK and Akt, as well as apply specific inhibitors to these proteins.  This will help 
reveal the exact mechanism by which signaling changes.  
In general attachment and proliferation experiments had difficulty discerning alteration in 
cell behavior.  While the results may be accurate there are a few additional reasons why our 
experiments did not show a strong change in cell behavior.  First, the proliferation and attachment 
experiments were not very sensitive.  Cell seeding density was intended to be consistent, but this 
may not have been the case due to cell settling or small differences in the volume of cell 
suspension used.  Furthermore, because the attachment measurements were taken 24 hours after 
cell seeding, both attachment and proliferation may have occurred.  In the future, more accurate 
measurements and varying methods of measuring cell attachment and proliferation should be 
employed to verify our results.  These could include immunofluroscent imaging of adhesion 
molecules like intregrins and vinculin for attachment quantification and the BrdU or MTT assays 
to measure proliferation.  Additionally, Akt signaling results should be correlated with cell death 
experiments (specifically apoptosis) to strengthen our claim that FGF2-mediated pAkt signaling 
of EC is dysfunctional in hyperglycemia.  These could be performed by flow cytometry assays 
(Annexin-Propidium iodide), the TUNEL assay, caspase assay, or live/dead assay.  
In conclusion vascular cell behavior changes with FGF2 in diabetic culture conditions. 
EC survival signaling decreased, while proliferation related signaling of EC and SMC did not 
change in hyperglycemic culture.  In chapter two we showed that EC BM-FGF2 binding changes 
under flow and that FGF2 levels in BM and culture medium change with fluid flow.  Together 
these results enrich our understanding of the effect of FGF2 on vascular cells under physiological 
conditions and indicate that the changes in FGF2 binding and release may in fact play a part in 
EC and SMC dysfunction in hyperglycemia. 
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5.  CONCLUSIONS AND FUTURE WORK  
 
5.1 Conclusions  
 Diabetes is approaching epidemic proportions worldwide. People with diabetes are at 
high risk of early and accelerated atherosclerosis, and they further experience elevated rates of 
restenosis following stent placement.  EC and SMC dysfunction in diabetic hyperglycemia is 
believed to play an important role in these processes, both by directly affecting cells and through 
BM collagen glycation. FGF2 may also be critical to loss of vascular homeostasis.  Though BM-
FGF2 binding is well understood under static conditions, these data do not account for the BM’s 
constitutive exposure to flow. EC and SMC FGF2 response has been characterized in 
normoglycemic conditions, but the cell FGF2 response in hyperglycemia has not been studied.  In 
this thesis we investigated FGF2 interaction with the BM under fluid flow, as well as with 
vascular cells in hyperglycemic conditions.  
 FGF2 equilibrium binding varied with shear stress possibly by a catch-slip mechanism, 
since BM-FGF2 binding peaked at a shear stress of around 25 dynes/cm
2
.  Fluid flow rapidly 
diminished non-specific binding to glass while specific BM-FGF2 binding was maintained. 
Interestingly, BM-FGF2 isolated after EC were exposed to 5 dynes/cm
2
 shear stress increased 
more than twofold over static conditions, while a shear stress of 20 dynes/cm
2
 did not change 
BM-FGF2 levels.  
A computational model of BM-FGF2 interaction incorporating convective-diffusive 
transport and a surface binding reaction was also created. Simulations demonstrated that 
convective transport governed time to equilibrium, while BM-FGF2 binding kinetics controlled 
equilibrium binding. Incorporation of the catch-slip mechanism into the model produced results 
which closely resembled experiments.  
EC and SMC proliferation and intracellular signaling in response to FGF2 were 
investigated under hyperglycemic conditions, including for cells grown on glycated collagen or in 
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high glucose culture. SMC and EC attachment did not vary with culture condition. FGF2 
increased cell proliferation compared to non-stimulated controls.  Neither EC nor SMC 
proliferation changed as a function of glucose concentration when cells were treated with FGF2. 
FGF2-stimulated SMC proliferation did not change with coating, but FGF2-stimulated EC 
proliferated less on collagen than glycated collagen.  Finally, EC pAkt signaling in response to 
FGF2 decreased on glycated collagen while pERK signaling did not change. 
These results suggest that forces encountered by HSPG-FGF2 complexes may regulate 
BM FGF2 binding, an important consideration when studying vessel response to intimal or EC 
damage.  This improved understanding of BM-FGF2 binding with flow enriches current FGF2 
binding kinetics knowledge and serves as an initial step in a comprehensive model of FGF2 
binding to cells and BM with flow.  Furthermore, our data suggests that EC and SMC response to 
FGF2 in hyperglycemia may contribute to dysfunctional cell behavior including increased EC 
apoptosis.  Taken together, these data motivate development of improved growth factor 
treatments by improving our understanding of growth factor kinetics under physiological and 
disease conditions.  If BM-FGF2 binding is in fact sensitive to shear stress, drug delivery 
therapies targeting exposed BM may be feasible.  Imitation of the BM-FGF2 binding site could 
also inspire new drug delivery systems in which drug release is sensitive to fluid forces.  Lastly, 
our results reveal that FGF2 binding kinetics assays should be performed under relevant 
physiological conditions to more accurately characterize and understand the role of fluid flow in 
vascular changes in hyperglycemia.  
 
5.2 Future Work 
We demonstrated that FGF2 binding changed with shear stress.  However, the 
mechanism explaining this process remains to be elucidated.  Therefore future work will include 
experimental measurement of the BM-FGF2 dissociation constant at various shear stresses. 
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Transient modulation of HSPG conformation with flow should also be investigated to see if the 
accessible BM HSPG binding site number causes variation in BM-FGF2.  Additionally, in our 
experiments we only varied shear stress which did not allow us to separate the effect of shear rate 
from fluid viscosity.  Therefore in future experiments the shear rate will be varied by changing 
the fluid viscosity and keeping shear stress constant; this will help us better understand the 
mechanism through which fluid flow affects BM-FGF2 binding.  Lastly, BM-FGF2 binding in 
flow with an intact EC layer and cell surface FGF2 binding with flow should be experimentally 
measured.  These studies will allow for a more complete understanding of the effect of fluid flow 
on FGF2 binding kinetics in the vasculature.  
Our model helped to explain the change in BM-FGF2 binding with fluid flow.  However, 
future model designs should include improvements to more accurately recreate blood vessel 
physiology and anatomy.  First, future models should be complete three dimensional cylinders 
where the vessel wall has the layers of and thickness similar to natural tissue.  Additionally the 
model should include relevant biomechanical properties including vessel compliance and 
dynamic response to pulsatile flow.  Future models should allow for variation of the flow profile 
to recreate the pulsatile flow experienced in vivo.  Ideally an EC layer with HSPG and FGFR 
binding sites should also be included, as well as FGF2creation and depletion.  
 FGF2 affected EC and SMC behavior in hyperglycemic conditions.  We showed that EC 
pAkt signaling was decreased on glycated collagen.  However in order to determine the exact 
mechanism by which FGF2 in ineffective at preventing EC death in hyperglycemia more specific 
experiments should be conducted.  Upstream and downstream signaling molecules in the Akt 
pathway should be examined.  Cell proliferation and attachment assays had difficulty discerning 
differences in cell behavior.  More sensitive methods to measure cell proliferation such as cell 
cycle analysis could be performed.  Immunofluorescent imaging of cell adhesion molecules and 
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the cytoskeleton could also help to clarify differences in cell attachment to normal and glycated 
collagen. 
 This research improves our understanding of what may occur during atherosclerosis and 
restenosis in people with diabetes and with future work aids development of new clinical 
therapies.  The change in BM-FGF2 binding with flow urges researchers and pharmaceutical 
companies to consider the effect of applied forces on binding kinetics.  BM-FGF2 binding may 
allow for targeted delivery of drugs which can be delivered to the exposed BM when EC are 
removed or damaged.  For example, conjugation of a peptide which mimics the characteristics of 
BM-FGF2 binding to a drug-eluting particle will enhance specific binding to exposed BM.  The 
inability of FGF2 to effectively prevent cell death through the Akt pathway also may be a 
possible drug target.  Reinforcement of the Akt pathway through an FGF2 agonist should help 
restore healthy regulation of EC turnover.  Loading such a drug into peptide-conjugated particles 
would specifically deliver the drug to areas in the vasculature where it is needed.  This approach 
would help to restore healthy function of the endothelium in the hopes of preventing diabetic 
complications.    
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